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 Skeletal muscle regeneration involves a tightly regulated coordination of cellular 
and signaling events to remodel and repair the site of injury.  When this coordination is 
perturbed, the regenerative process is impaired.  The expression of insulin-like growth 
factor-I (IGF-I) is robust in the typical muscle regenerative program, promoting cell 
survival and increasing myoblast activity.  In this project, we found that severely 
depressed IGF-I expression and intracellular signaling in aged skeletal muscle coincided 
with impaired regeneration from ischemia/reperfusion (I/R).  To hasten muscle 
regeneration, we developed the PEGylated fibrin gel (PEG-Fib) system as a means to 
intramuscularly deliver IGF-I in a controlled manner to injured muscle.  This strategy 
resulted in greatly improved muscle function and histological assessment following 14 
days of reperfusion, which are likely mediated by improved myofiber survival.  Recent 
evidence suggests macrophages (MPs) are responsible for the upregulation of IGF-I 
following injury, therefore we developed a rapid, reproducible, and cost-effective model 
of investigating MP profiles in injured muscle via flow cytometry.  Using information 
gathered from this model, we found that increasing the number of a non-inflammatory 
MP population improves the recovery of muscle from I/R.  These data demonstrate that 
immunomodulatory therapies have the potential to greatly improve the recovery of 
skeletal muscle from injury.  
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Chapter I:  General Introduction 
 Skeletal muscle injury involves a complex program of degenerative and 
regenerative activities to repair the damaged tissue and restore contractile muscle 
function.  Coordination of these processes is achieved by an orchestra of molecules, 
including intracellular components, cytokines/chemokines, growth factors, and protease 
byproducts, which create a milieu that directs the cellular constituents of the injury site to 
their proper state of activation in order to promote efficient skeletal muscle regeneration.  
Insulin-like growth factor-I (IGF-I), a peptide growth factor, is one of these post-injury 
components that has received considerable attention for its role in the muscle 
regenerative process, as it promotes myoblast activity [1], its activity is required for 
efficient regeneration [2], and its forced overexpression greatly facilitates regeneration [3, 
4].  Thorough understanding of the biology of this fascinating molecule not only has the 
potential to lead to improved therapies of healthy individuals with muscle injuries, but 
also can be utilized to understand and treat individuals whose skeletal muscle injuries 
may resulting in disablement and/or mortality, such as the growing elderly population. 
OBJECTIVES 
 The overall objective of this research project is to gather a broad understanding of 
IGF-I biology in muscle regeneration.  Using tourniquet (TK)-induced 
ischemia/reperfusion (I/R) of the rodent hind limb as our injury model, we sought to 
accomplish the following aims: 
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1) Characterize the IGF-I response to I/R in young, healthy animals, and compare 
those results to aged animals, which serve as a population that exhibits 
regenerative impairments. 
2) Develop an IGF-I based therapy using PEGylated fibrin gel as a delivery platform 
to improve functional recovery of muscle following I/R. 
3) Generative a model to allow for investigation of inflammatory components  in 
post-injury skeletal muscle, as they may be responsible for IGF-I regulation. 
HYPOTHESES 
1) Healthy muscle will display robust IGF-I upregulation in response to I/R. 
2) Aged muscle will exhibit an attenuated IGF-I response in addition to regenerative 
impairments. 
3) PEGylated fibrin gel-mediated delivery of IGF-I will improve functional recovery 
of skeletal muscle following I/R. 
4) Post-injury macrophage profile modification can substantially affect skeletal 
muscle regeneration following I/R. 
SIGNIFICANCE 
 The present work provides valuable insights into the biology of IGF-I in muscle 
regeneration, primarily in the context of therapeutic application.  While the clinical utility 
of the approaches and results presented here may be questionable for healthy muscle, 
where the intrinsic regenerative drive is robust, they may provide incredible opportunities 
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for therapeutic development for individuals with compromised ability to undergo muscle 
regeneration, such as the elderly. 
DELIMITATIONS AND LIMITATIONS 
 This work was completed on rodents using TK-induced I/R as an injury model, 
and therefore may not necessarily apply to other species or injury models.  Experiments 
validating the broad applicability of the current findings would need to be performed.  In 
addition, volumes utilized in this work would need to be optimized for larger species 















Chapter II: Review of the Literature 
SKELETAL MUSCLE INJURY AND REPAIR 
Inflammatory response 
The injury-induced inflammatory response of skeletal muscle is a complex, 
temporally-orchestrated process that involves an initial infiltration of neutrophils, 
followed by subsequent infiltration of macrophages [Reviewed by 5].  The number of 
neutrophils increases substantially as early as 2 hours and peaks in ~6 hours in reloaded 
soleus muscles of previously hindlimb-suspended rats [6].  This early infiltration of 
neutrophils is responsible for additional muscle damage caused by the inflammatory 
response [6].  Additional damage is due to a superoxide-dependendent mechanism [7].  A 
population of macrophages characterized by positive immunostaining for the cell surface 
marker ED1 (rat specific) infiltrate the injured muscle and peak in prevalence at ~ 2 days 
after reloading [8].  These cells have been shown to invade and phagocytose 
injured/degenerating muscle cells [8, 9].  A second population of ED2+ macrophages 
peak in prevalence ~4-7 days post-reloading [8].  These cells are often classified as 
resident macrophages that do not undergo phagocytosis of necrotic debris [9, 10], yet 
have a supportive role in muscle regeneration [11, 12].   
Geissmann et al. [13] identified distinct inflammatory CX3CR1low/Ly6-C+ and 
non-inflammatory CX3CR1high/Ly6-C- subsets of macrophages in the mouse, which 
correspond to  CD14+/CD16- and CD14low/CD16+ populations in humans.  Arnold et al. 
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[14] demonstrated that CX3CR1low/Ly-6C+ cells show high expression of the 
inflammatory cytokines TNF-α and IL-1β, and that exposure to and subsequent 
phagocytosis of necrotic tissue cause CX3CR1low/Ly-6C+ cells to shift to the 
CX3CR1high/Ly6C- phenotype and express the anti-inflammatory cytokines TGF-β1 and 
IL-10 in vitro. 
Myogenic Regeneration 
The repair of injured myofibers is mediated by muscle-specific stem cells known 
as satellite cells.  These cells are the primary source of myonuclei to repopulate injured 
skeletal muscle [Reviewed by 15].  Other types of cells, including circulating 
hematopoietic stem cells [16] and side-population cells [17], have been shown to have 
myogenic potential, but their involvement in muscle regeneration is small relative to that 
of satellite cells.   
In uninjured muscle, satellite cells reside in a quiescent state between the 
sarcolemma and basal lamina [18].  In their quiescent state, satellite cells can be 
identified by their expression of Pax7 [19, 20].  Following an unknown stimulus induced 
by muscle injury, quiescent satellite cells are activated by a p38-dependent mechanism, 
induced to enter the cell cycle, and begin a stage of rapid proliferation [21].  Actively 
proliferating satellite cells are characterized by the expression of the myogenic regulatory 
factor MyoD [21-23].   
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Following the proliferative stage, the satellite cells begin to differentiate into 
myotubes, which then fuse into the injured myofiber.  At this time, the cells reduce 
expression of MyoD and begin expression of myogenin [23].  The presence of central 
nuclei in a myofiber is evidence of a recently fused myotube.  The central myonuclei 
typically move towards the periphery as the myofiber matures. 
Decline in Regenerative Capacity with Age 
The age-related decrement of skeletal muscle, termed sarcopenia, is largely 
characterized by the progressive loss of muscle mass, muscle strength, and reduced 
responsiveness to anabolic stimuli [24]. Skeletal muscle also exhibits a reduced 
regenerative capacity with age, characterized by loss of myoblast function, exacerbated 
loss of muscle mass, and reduced recovery of function [25, 26]. Strong evidence 
demonstrates this age-related impairment in regeneration is heavily influenced by 
diffusible factors, as evident by rejuvenation of aged muscle in both models of 
heterochronic muscle transplantation [27]  and parabiosis of heterochronic mice [28]. 
 
IGF-I EFFECTS IN SKELETAL MUSCLE 
General IGF-I Signaling and Skeletal Muscle Effects 
IGF-I is an anabolic, liver-derived endocrine growth factor in the growth hormone 
axis that is also released in autocrine/paracrine fashion in many tissue types, including 
skeletal muscle [Reviewed by 29].  Activation of the IGF-I receptor, a tyrosine kinase, by 
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the binding of IGF-I induces a vast array of effects on skeletal muscle, including 
promotion of muscle hypertrophy [30-33], prevention of muscle atrophy [34-37], 
prevention of cell death by apoptosis [Reviewed by 38], and the potent stimulation of 
both myoblast proliferation and differentiation [1, 24, Reviewed by 29, 39].  Studies 
using pharmacological inhibitors to assay the activity of IGF-I on cultured myoblasts 
have shown that the proliferative activity of IGF-I is mediated by the MAPK/ERK 
pathway and the PI3K/Akt pathway is responsible for the differentiation-promoting 
activity [40]. 
IGF-I in Muscle Regeneration 
IGF-I upregulation is induced in muscle by an injury stimulus. Following I/R, 
IGF-I mRNA increases within 24 hours of reperfusion, and peaks at 3 days [41]. This 
induction of IGF-I was observed in hypophysectomized rats, thus is independent of 
growth hormone actions [41]. The autocrine/paracrine actions of IGF-I on injured muscle 
is multi-faceted, as it promotes cell survival, stimulates myoblast proliferation, and 
induces myoblast differentiation [1]. Muscle-specific IGF-I over-expression causes 
muscle hypertrophy [32] and enhances muscle recovery following injury [4]. 
The cellular source of IGF-I expression in response to injury is a topic of 
controversy, as most reports of IGF-I upregulation, whether peptide or mRNA, is from 
whole muscle tissue.  In histochemical studies, the localization of IGF-I is inconsistent, as 
well.  IGF-I immunoreactivity following ischemia reperfusion injury of the EDL is said 
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to be localized to satellite cells, myoblasts, blood vessels, and nerves, with no IGF-I 
immunoreactivity in intact myofibers [42].  However, it is not clear how these 
investigators differentiated specific cell types among the mesh of IGF-I+ mononuclear 
cells.  A similar result was reported in a subsequent study involving myotoxin induced 
injury [43], and by another research group using a cryo-injury model [44].  In situ 
hybridization for IGF-I mRNA expression following ischemia/reperfusion injury supports 
the same conclusion [41].  In contrast, Keller et al. [45] report IGF-I immunoreactivity 
only in regenerating myofibers of eccentrically damaged soleus muscle and not in the 
supporting mononuclear cells.  However, due to the methodology of electrical 
stimulation-induced eccentric damage on soleus muscle, IGF-I expression within mature 
myofibers may be caused by mechanical stimulation alone [46] and not by substantial 
myofiber damage.   
Decline in IGF-I Responsiveness with Age 
IGF-I mRNA is decreased with age in human muscle [47].  Aged muscle 
demonstrates attenuated IGF-I induction following TK-induced I/R [26] and mechanical 
loading [48].  Muscle-specific IGF-I over-expression prevents the sarcopenic phenotype 
[3, 49], and enhances the recovery aged muscle following injury [3].  Our group has 
demonstrated the induction of IGF-I is reduced with age following I/R injury [26, 50]. 
Macrophages and IGF-I 
 9 
There is evidence that macrophages are involved in the local induction of IGF-I 
following muscle injury.  In addition to being necessary for normal muscle regeneration 
[14, 51-55], macrophages have been shown to express IGF-I [56, 57].  Furthermore, 
recent studies investigating muscle regeneration with clodronate liposome macrophage-
depletion demonstrated that IGF-I gene expression is significantly reduced in the absence 
of invading macrophages [54, 58].  Lu et al. [59] recently demonstrated that post-injury 
IGF-I expression is largely dependent on the infiltration of CCR2+ monocytes, and that 
















Chapter III:  Impairment of IGF-I Expression and Anabolic Signaling following 




 With the advancement of age, skeletal muscle undergoes a progressive decline in 
mass, function, and regenerative capacity.  Previously, our laboratory has reported an 
age-reduction in recovery and local induction of IGF-I gene expression with age 
following tourniquet (TK)-induced skeletal muscle ischemia/reperfusion (I/R).  In this 
study, young (6 mo) and old (24-28 mo) mice were subjected to 2 hours of TK-induced 
ischemia of the hindlimb followed by 1, 3, 5, or 7 days of reperfusion.  Real time-PCR 
analysis revealed clear age-related reductions and temporal alterations in the induction of 
IGF-I.  ELISA verified a reduction of IGF-I peptide with age following 7 days recovery 
from TK.  Western blotting showed that the phosphorylation of Akt, mTOR, and FoxO3, 
all indicators of anabolic activity, were reduced in the muscles of old mice.  These data 
indicate an age-related impairment of IGF-I expression and intracellular signaling does 
exist following injury, and potentially has a role in the impaired recovery of skeletal 





Sarcopenia is the progressive decline in skeletal muscle mass and function with 
advanced aging [See 24, 25 for review].  The skeletal muscle of aged individuals also 
demonstrates more susceptibility to injury [60, 61] and impaired regeneration following 
injury [26, 62, 63], suggesting that these characteristics are included in the sarcopenic 
phenotype.  Investigations of muscle regeneration in heterochronic muscle transplantation 
[27] and parabiosis [28] models demonstrate that muscles of aged animals regenerate 
similarly as those of young when exposed to a young systemic environment.  This 
indicates that diffusible, extrinsic factors have a substantial influence on intrinsic cellular 
processes in the age-related decline in muscle regenerative capacity, and suggests 
autocrine/paracrine growth factor(s), such as IGF-I, play a role in this phenomenon.   
Surgical use of pneumatic tourniquets (TK) on the extremities occurs over 20,000 
times a day worldwide in order to prevent excessive blood loss and provide a bloodless 
surgical field [64].  Their prolonged use results in a severe ischemia reperfusion (I/R) 
injury of the affected skeletal muscle [65], defining a very clinically-relevant problem.  
Considering the large proportion of orthopedic surgeries performed on elderly 
individuals, the extent of damage and subsequent recovery of aged skeletal muscle from 
TK-induced I/R is a topic of importance.  Our laboratory has shown that skeletal muscles 
of aged rats have greater functional deficits than young following 7 and 14 days of 
recovery from TK-induced I/R injury, and an age-associated defect in the local induction 
of IGF-I is a potential mechanism contributing to this phenomenon [26]. 
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Local induction of IGF-I in skeletal muscle occurs in various models of muscle 
injury [41-44, 66, 67].  The role IGF-I plays in injured muscle includes cell survival, 
satellite cell proliferation, and satellite cell differentiation [See 24, 39 for review, 68].   
The specific aim of the present study was to compare the time course of IGF-I 
gene expression, protein levels, and signaling cascades in the skeletal muscle of young 
and old mice following TK-induced I/R.  We found clear age-related alterations in the 
relative quantities and temporal patterns of IGF-I gene expression in our model of injury.  
In addition, TK-injured aged skeletal muscle exhibits deficits in IGF-I peptide levels and 
anabolic signaling downstream of the IGF-I receptor.  These data further support our 
hypothesis that an age-associated decrease in IGF-I induction following injury is a 
potential cause of the impaired regeneration of aged skeletal muscle.   
METHODS 
Animals 
 Young (6 mo) and old (24-28 mo) male C57BL/6 mice were used for this study.  
Animals were housed individually with ad libitum access to food and water, and 
maintained on a 12-hour light/dark cycle.  Age-separated mice were randomly assigned 
into 1, 3, 5, and 7-day recovery groups.  All experimental procedures were approved and 




Mice were anesthetized with 2% isoflurane gas prior to and for the duration of 
tourniquet application.  A single, randomly selected hind limb was elevated, and a 
pneumatic tourniquet (D.E. Hokanson, Inc.) was wrapped snuggly against the proximal 
portion of the limb and inflated to 250 mm Hg by the Portable Tourniquet System (Delfi 
Medical Innovations Inc.) to ensure complete occlusion of blood flow to the limb for a 
duration of 2 hours [69].  Body temperature was maintained at 37±1º C with the use of a 
heat lamp during this procedure.  After 2 hours, the pneumatic tourniquet was removed, 
and the mouse was returned to its cage for recovery.  For all measures, muscles from the 
uninjured contralateral limb served as internal controls, as performed in other studies [26, 
70, 71]. 
Force Measurements 
Gastrocnemius muscles were surgically isolated from all other muscles and 
connective tissue, and subjected to functional measurements.  The Achilles tendon was 
secured to the muscle lever arm of a servomotor (model 305B, Cambridge Technologies) 
interfaced with a computer equipped with an A/D board (National Instruments).  The 
muscle was stimulated to contract using an Isolated Pulse Stimulator (Model 2100; A-M 
Systems) with leads applied to the sciatic nerve.  Muscle temperature was kept constant 
at 37º C with warm mineral oil and a radiant heat lamp throughout the procedure.  
Optimal length of the muscle was determined by measuring maximal twitch tension at a 
stimulation of 0.5 Hz.  At optimal length, the muscle was stimulated at 150 Hz to elicit 
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the peak tetanic tension (Po), and was allowed 2 minutes of rest between each contraction.  
Data were stored and analyzed using LabView software (National Instruments). 
Tissue Harvesting 
 The hind limb muscles were quickly harvested from both the TK and contralateral 
leg, and frozen in liquid nitrogen-cooled isopentane and stored at -80° C until later 
analysis.  Plantaris muscles were fixed in 10% formalin for histological evaluation.  Mice 
were euthanized with an overdose of sodium pentobarbital (100mg/kg). 
Histological Analysis 
 Formalin-fixed muscles were embedded in paraffin wax, cut into 5 µm thick cross 
sections, and stained with hematoxylin & eosin (H&E).  Slides were evaluated using an 
Olympus BX41 microscope at 4, 10 and 40 X magnification.  Images were captured at 40 
X magnification using an Olympus BX41 microscope and an Olympus DP71 digital 
camera. 
F2-Isoprostane levels 
Levels of F2-isoprostanes (IsP), byproducts of lipid peroxidation and an indicator 
of oxidative stress, were measured, as previously described [72], in the gastrocnemius of 
2 hour, 24 hour, and 5 day recovery groups of young mice (n = 6), and in 24 hour and 5 
day recovery groups of old mice (n = 6) using gas chromatography.  The levels are 
indicated as nanograms of IsPs per gram of muscle tissue. 
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RT-PCR 
Real-time PCR experiments were performed as previously described [26].  RNA 
was extracted from EDL muscles using RNA-STAT (Tel-Test, Friendswood, TX).  
Samples underwent chloroform extraction and centrifugation, followed by precipitation 
in isopropanol at -20º C.  Precipitated RNA was centrifuged, the supernatant removed, 
and the pellet dissolved in nuclease-free water.  RNA was quantified on a 
spectrophotometer at a wavelength of 260 nm.  Conversion of total RNA to single-strand 
cDNA was accomplished using the High-Capacity cDNA Archive Kit (P/N 4322171; 
Applied Biosystems; Foster City, CA).  Briefly, 5 – 10 µg total RNA were reverse 
transcribed using random primers for the following incubation times:  25º C for 10-
minutes, then 37º C for 2 hours.  cDNA samples were stored at -80º C until use. 
RT-PCR was performed on cDNA using commercially available (mouse 18S, 
ABI P/N Hs99999901_s1 and IGF-I, ABI P/N Mm00439561_m1, exon boundary 3-4) 
hydrolysis primers and probes.  The PCR reaction was performed in an ABI 7500 thermal 
cycler with the fluorescence of 3 to 15 cycles was set as background. Data was collected 
at the annealing step of each cycle, and the threshold cycle (Ct) for each sample 
calculated by determining the point at which the fluorescence exceeded the threshold 
limit.  Standard curves for each probe/primer pair were established by serial 10-fold 
dilutions of cDNA of known concentrations, and the Ct values from samples were plotted 
along the curves to obtain relative values.  All samples were then normalized to 18S 
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rRNA.  Data points represent the average of two to three runs, each in duplicate, and each 
performed on separate cDNA synthesis reactions. 
ELISA 
Tissue levels of IGF-I were measured by a method similar to that described by 
D’Ercole et al. [73], with minor modifications.  Briefly, ~100 mg of frozen muscle tissue 
(tibialis anterior + EDL muscles) were powdered under liquid nitrogen and suspended in 
5 mL of acetic acid per gram of tissue.  Tissue suspensions were incubated on ice for 30 
minutes and insoluble material was removed by centrifugation (10 minutes @ 5,000 g, 4º 
C).  Extracts were lyophilized and resuspended in 0.1 M Tris (pH 8.0) at 2 mL/g of 
tissue.  Samples were cleared by centrifugation (10 minutes @ 10,000 g, 4º C).  Protein 
concentrations of cleared lysates were determined by the method described by Bradford 
[74].  An equal amount of protein was used to determine the IGF-I content using an IGF-I 
ELISA kit (Immuno Diagnostic Systems; Fountain Hills, AZ).  Input volumes of the 
samples were increased to 25 µl, and the volume of diluent was decreased to 0.25 mL.  
The remainder of the assay was performed according to the manufacturer’s instructions. 
SDS-PAGE 
 Samples from control and TK gastrocnemius muscles were homogenized at 4º C 
in a buffer containing 50 mM HEPES (pH 7.6), 150 mM NaCl, 1% Triton-X 100, 20 mM 
β-glycerol phosphate, 10 mM NaF, 1 mM Na3VO4, 10 ng/mL each of leupeptin and 
aprotinin, 1 mM PMSF, and 1:100 dilutions of phosphatase inhibitor cocktails 1 & 2 
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(Sigma-Aldrich).  The resulting homogenate was centrifuged at 12,000g for 30 minutes, 
and the supernatant was kept for analysis.  Protein concentrations of all samples were 
determined as described by Bradford [74].  Samples were boiled in 4X Laemmli’s sample 
buffer at a ratio of 3:1, and equal amounts of total protein were loaded into each well of a 
5% stacking/15% separating polyacrylamide gel.  Gels were run at constant current until 
necessary protein separation was achieved.   
 To verify equal loading of protein content among lanes, Coomassie blue staining 
of randomly selected gels was performed following SDS-PAGE separation.  Gels were 
washed in dH2O for 30 minutes, incubated in Bio-Safe Coomassie blue solution (Bio-
Rad) for 1 hour, and washed again in dH2O overnight.  Gel images were taken using the 
Chemidoc XRS system (Bio-Rad).  Volumetric analysis of all bands of each lane was 
performed using Quantity One software to verify that there were no substantial 
differences in total protein content despite differences in distribution of protein content 
between groups.  
Western Blotting 
Following SDS-PAGE separation, proteins were transferred to a PVDF membrane 
(Millipore) and blocked with 5% milk in 0.1% Tween 20 in TBS (TBST) for 1 hour.  
Ponceau-S staining was performed to ensure equal transfer prior to blocking.  Membranes 
were incubated in 1:1000 dilutions of primary antibody in either 1% milk-TBST or 5% 
BSA-TBST overnight at 4° C, then in 1:2000 dilutions of goat anti-rabbit HRP 
 18 
conjugated secondary antibody (Pierce) in either 1% milk-TBST or 5% milk-TBST for 2 
hours.  Blots were visualized by ECL detection (Perkin-Elmer) using the Chemidoc XRS 
system (Bio-Rad).  Band volumetric analysis was performed using Quantity One 
software.  Following ECL detection of phospho-proteins, membranes were stripped and 
re-probed for total protein.  Anti-phospho-mTOR (Ser 2448; 2971), anti-phospho-
FoxO3a (Ser 253; 9466), anti-Akt (9272), anti-mTOR (2972), and anti-FoxO3a (9467) 
primary antibodies were purchased from Cell Signaling Technology.  Anti-phospo-Akt 
1/2/3 (Ser 473; sc-7985-R) primary antibody was purchased from Santa Cruz 
Biotechnology.  All experiments were repeated in triplicate to verify results. 
Data Analysis 
 All values are expressed as mean ± SEM.  Statistical analysis involved two-factor 
ANOVA (age and TK treatments; Tukey post-hoc tests) or Student’s t-tests, where 
appropriate, using SPSS 16.0 software (α = 0.05). 
RESULTS 
Functional Evaluations 
Previously, we have reported that rats exhibit age-related increases in functional 
deficits of the plantar flexor muscles following 7 and 14 days recovery from 2 hour TK-
induced I/R injury [26].  To verify that a similar phenomenon occurs in a mouse model, 
young and old mice were evaluated for maximum force production of the gastrocnemius 
in situ after 7 days of reperfusion (Figure 3.1).  At 7 days post-TK, young and old 
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animals demonstrated functional deficits of 67 and 78%, respectively (p ≤ 0.05 between 
the age groups).   
Muscle Mass 
Figure 3.2 depicts the wet masses of all GAS muscles obtained in this study.  In 
general, TK-injured muscles increased in mass 1 day post-TK, and this increase remained 
elevated through 3 days.  Histological evidence confirmed this early post-TK increase 
coincides with edema and swelling of the myofibers.  Following day 3, muscle masses of 
both age groups demonstrated progressive declines until day 7, when young and old 
muscles demonstrated significant decreases of 13 and 22% decreases in mass, 
respectively.  At this time, the muscle mass of old mice was 27% lower than that of 
young.  This decrease in old represents a 38% greater loss of mass, relative to day and 
age-matched controls, than the loss observed in young.   
Histology 
 H&E-stained plantaris muscle cross-sections from young and old 1, 3, 5, and 7-
day recovery mice were evaluated (Figure 3.3).  Control muscles from both young and 
old animals demonstrated no pathology, exhibiting angular fibers with peripheral nuclei.  
Following 1 day of recovery from I/R, old muscle demonstrated a higher degree of 
swelling (rounding of the myofibers), edema, neutrophil infiltration, and internalization 
of nuclei than young.  Both age groups demonstrated a comparable degree of multifocal 
degeneration and necrosis.  Similarly at day 3, old muscles demonstrated more myofiber 
 20 
swelling, edema, and infiltration of macrophages.  Young muscles exhibited similar 
neutrophil infiltration as that observed in old, following injury, but revealed higher 
degrees of multifocal degeneration, necrosis, and internalized nuclei; neutrophil 
infiltration was similar to that of old.  Old muscles in the 5-day recovery group exhibited 
similar degrees of degeneration/necrosis as those of young, yet had more severe instances 
of edema, infiltration of neutrophils and macrophages, and internalization of nuclei.  Old 
muscles demonstrated a higher incidence of centrally located nuclei (i.e. regeneration) at 
this time, suggesting more damage had incurred.  At 7 days, young and old muscles had 
similar degrees of edema, degeneration, and infiltration of neutrophils and macrophages; 
old muscles demonstrated higher amounts of swelling and regeneration than young at this 
time. 
Lipid peroxidation 
 I/R injury has traditionally been largely attributed to oxidative stress caused by 
the generation of reactive oxygen species (ROS).  To test the prevalence of oxidative 
stress in our 2 hour TK model, we measured IsPs, by-products of the lipid peroxidation 
reaction and a good indicator of oxidative stress in vivo [75], in the gastrocnemius 
muscles of young and old mice (Figure 4.4).  In young mice, IsPs were elevated as soon 
as 2 hours post-TK, and remained elevated through the 5-day recovery mark (p ≤ 0.05 for 
all times).  IsP levels were also elevated in the muscles of old mice, as seen at 1 and 5 
days post-TK (p ≤ 0.05 for both times).  This demonstrates that oxidative stress occurs 
quickly and is persistent in our model of TK-induced I/R.   
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IGF-I gene expression 
The local induction of IGF-I mRNA in skeletal muscle following an injury 
stimulus is well documented [26, 41, 66, 67].  Using our model of muscle injury, IGF-I 
mRNA in control and TK EDL muscles were measured by RT-PCR and were quantified 
relative to young 1 day control values (Figure 3.5A), revealing both a quantitative and 
temporal shift with age in the first 7 days of reperfusion.  TK-induced injury resulted in 
significant increases in IGF-I gene expression at days 1, 3, and 7 post-TK in both young, 
and at days 3, 5, and 7 in old compared to their respective controls.  In young, IGF-I 
mRNA displayed a robust peak 3 days post-TK, while the old showed a delayed and 
quantitatively diminished peak at day 5.  Old mice demonstrated significantly less TK-
induced IGF-I gene expression than young at days 1 and 3, and was higher in expression 
at its peak on day 5.  These data demonstrate temporal and quantitative impairment of 
IGF-I expression occurs with age following TK-induced injury.   
IGF-I peptide levels 
 Having observed that IGF-I mRNA decreased with age, we next sought to 
determine whether intramuscular immunoreactive IGF-I levels are also reduced.  A 
significant increase in IGF-I peptide following 7 days of recovery occurs in young, and 
not in old (Figure 3.5B).  These data indicate IGF-I peptide levels, in addition to mRNA, 
are reduced with age following TK-induced I/R.      
Akt, mTOR, and FoxO3 signaling 
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 To investigate the time-course of anabolic activity in young and old skeletal 
muscle following I/R, the phosphorylation of key proteins of the phosphoinositide 3-
kinase (PI3K)/Akt pathway were analyzed (Figure 3.6).  Early in recovery, levels of p-
Akt and total Akt diminished to almost undetectable levels in both young and old, with 
no difference between the ages.  At day 5, p-Akt content rose in the young mice, while 
old muscles still demonstrated no return of p-Akt signal.  Similarly, p-Akt levels were 
higher in the young than old at day 7 (p ≤ 0.05).  These data indicate an age-related delay 
in Akt activation following I/R injury. 
 Mammalian target of rapamycin (mTOR) is a crucial mediator of anabolic activity 
in skeletal muscle [See 76 for review].  There were no age-related differences in p-mTOR 
among age groups until day 7.  At this time, there were large increases in p-mTOR values 
in the young mice relative to day-matched control levels, which were higher than those of 
old mice (p ≤ 0.05), suggesting phosphorylation of mTOR is impaired/delayed in aged 
muscle recovering from I/R. 
 The FoxO class transcription factors (FoxOs) are targets of active Akt kinase 
activity.  In their active, unphosphorylated state, these proteins reside in the nucleus and 
promote gene expression of atrophy-stimulating genes, such as the E3 ubiquitin ligase, 
atrogin-1 [37].  Phosphorylation of FoxOs by Akt induces translocation from the nucleus 
and degradation in the cytosol [See 77 for review].  Content of p-FoxO3 followed the 
same pattern as p-mTOR.  After 7 days of recovery, p-FoxO3 content in young was 
substantially higher than old (p ≤ 0.05).  The physiological relevance of these signaling 
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deficits are strengthened by the exacerbated loss of mass in the muscles of old following 
TK application (Figure 3.2, Day 7). 
DISCUSSION 
 The substantial loss of muscle mass and function that result from TK use are a 
concern given the high proportion of elderly individuals who undergo orthopedic surgery, 
as muscle mass and strength are negatively associated with disability and mortality rates 
[See 78 for review].  The data presented in this study demonstrate clear age-related 
alterations in local IGF-I gene expression, IGF-I peptide levels, and anabolic signaling in 
skeletal muscle following I/R in mice.  In this study we present several novel findings 
including a correlation between IGF-I mRNA levels and protein levels in aged muscle 
and a reduction in intracellular signals generated by the IGF-I receptor. In addition, we 
find an elevation in potentially active FoxO in the muscle of aged animals. These novel 
findings extend our previous observations and provide important information regarding 
the potential mechanisms that underlie the reduced capacity for aged muscle to recover 
from injury. 
 Due to its pleiotrophic effects, IGF-I is an important molecule in the study of 
skeletal muscle response to injury.  IGF-I stimulates both the proliferation and 
differentiation of myoblasts via activation of the MAP kinase and PI3K/Akt pathways, 
respectively [40].  In differentiated muscle, IGF-I is hypertrophic and anti-atrophic, with 
both actions largely attributed to PI3K/Akt activation [30, 32-34, 36, 79].  IGF-I 
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overexpression also increases the recruitment of circulating bone marrow-derived stem 
cells [80, 81] and hastens the resolution of inflammation [4] following muscle injury.  
Additional benefits of  IGF-I may include protection of cells from oxidative stress [82, 
83], mitochondrial dysfunction [84], and apoptosis [See 38 for review], as seen in non-
muscle tissues. 
 Due to the positive effects of IGF-I, we hypothesize that the age-related 
impairment of IGF-I expression is a contributing factor to the general decrement of aged 
muscle following injury.  This is supported by evidence that the forced overexpression of 
IGF-I in the skeletal muscles of aged mice prevents the sarcopenic phenotype [3, 49] and 
protects injured muscles from the exacerbated decrement caused by aging [3].  In 
addition, the administration of IGF-I has the ability to restore the proliferative potential of 
satellite cells in atrophied aged muscles [85].  Despite these effects of IGF-I on 
sarcopenia, it was only recently shown that the injury-induced upregulation of IGF-I is 
impaired with age [26].  The present study verifies this age-related reduction in the 
injury-induced IGF-I expression exists in the mouse model of TK-induced I/R with the 
distinctive finding that a delay in peak expression also occurs, as young peak in 
expression at 3 days post-TK and old at 5 days post-TK.  We also verify that IGF-I 
peptide levels are reduced with age.  The merits of these findings are further strengthened 
by recent evidence that functional IGF-I receptors are required for the efficient 
regeneration of injured skeletal muscle, thereby highlighting the importance of IGF-I to 
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muscle regeneration [2].  This current line of evidence suggests that non-genetic, IGF-I-
based intervention may be an effective method of therapeutic intervention.   
  The skeletal muscle of  aged mice also demonstrate significant deficits in 
phosphorylation of Akt, mTOR, and FoxO3, all indicators of positive anabolic activity, 
compared to their young counterparts after 7 days of recovery from TK-induced I/R.  
Activation of the PI3K/Akt pathway leads to an increase in protein synthesis through a 
mTOR-dependent process [33, 86], and prevents atrophy through a mostly FoxO-
dependent process [37].  Indirect activation of mTOR by Akt initiates the activation of 
pro-translational signaling by the activation p70 S6 Kinase (p70S6K) and the deactivation 
of 4E-Binding Protein (4E-BP) through phosphorylation [86, 87].  The reduction of pAkt 
and pmTOR in old muscle suggests protein synthetic pathways are attenuated with age 
following I/R.  A similar delayed response of Akt activation in old rats was recently 
found to coincide with impaired hypertrophy using the functional overload model [88].  
The present data indicates that the mechanism responsible for the age-related decrease in 
signaling is prior to the activation of Akt, perhaps due to changes in IGF-I ligand levels. 
We are, however, limited by the fact that different muscles were used for mRNA/peptide 
and signaling assays.  We also cannot, at this time, discount the possibility of age-related 
alterations in the expression and/or activation of upstream mediators of Akt activation, 
such as the IGF-I receptor, IRS-1, and/or PI3K, or proteins downstream of mTOR, 
including mTORC1, p70S6K, 4E-BP, and/or ribosomal protein S 6.  
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Another important finding of the current study is the substantially reduced 
pFoxO3 levels in the TK muscles of old mice.  In differentiated muscle, active FoxO 
proteins are localized in the nucleus and activate transcription of the muscle-specific E3 
ubiquitin ligases Atrogin-1 and MuRF-1 [34, 37, 89] and many genes associated with 
autophagy [90-92], causing substantial atrophy.  In addition, FoxOs are responsible for 
the upregulation of the cell cycle inhibitor p27kip1, thereby preventing satellite cell 
proliferation [93, 94].  FoxOs have also been shown to induce apoptosis in vitro [95, 96].  
IGF-I mediated phosphorylation of FoxOs by Akt causes their exclusion from the 
nucleus, thereby preventing their transcriptional activity [34, 37].  These data suggest 
FoxO activity is elevated in TK-injured aged muscle, leading to an age-related increase in 
atrophy stimulation and/or reduced proliferative potential of satellite cells.   
In summary, the present data demonstrate that the local induction of IGF-I gene 
expression, IGF-I peptide levels, and signaling of the PI3K/Akt pathway in skeletal 
muscle are attenuated with age following I/R.  This result is clinically significant due to 
the growing elderly population and the large proportion of orthopedic surgeries within 
this demographic.  However, further investigation needs to address the mechanisms 
behind the age-related reduction in IGF-I response, i.e. whether it is due to extrinsic 
factors, intrinsic phenomena, or an interaction thereof.  Despite this, the results of this 
study strengthen the use of IGF-I based therapy as a potential treatment to promote 








Figure 3.1. Maximum force production of gastrocnemius muscles from 6 mo (young) 
and 24-27 mo (old) C57BL/6 mice was evaluated in situ following 7 days of recovery 
from I/R.  Values are represented as mean ± SEM; *p ≤ 0.05 vs. treatment-matched 













































Figure 3.2. Wet masses of gastrocnemius muscles (A) were measured from 6 mo (young) 
and 24-27 mo (old) C57BL/6 mice following 1, 3, 5, 7 days of recovery from 2 hour TK-















































Figure 3.3. Plantaris muscles from 6 mo (young) and 24-27 mo (old) C57BL/6 mice 
were paraffin-embedded and stained with hematoxylin & eosin following 1, 3, 5, and 7 

















Figure 3.4. F2-isoprostanes were measured in the gastrocnemius muscles of 6 mo (young) 
C57/BL6 mice following 2 hours, 1 day, and 5 days of reperfusion and of 24-28 mo (old) 
mice following 1 day and 5 days of reperfusion.  Values are represented as mean ± SEM; 
















































Figure 3.5. Real time-PCR was performed to measure relative expression of  IGF-I 
mRNA in the extensor digitorum longus muscle of 6 mo (young) and 24-27 mo (old) 
C57BL/6 mice following 1, 3, 5, and 7 days of recovery from 2 hour TK-induced I/R (A).  
Whole tissue IGF-I peptide levels were measured by ELISA in the tibialis anterior and 
extensor digitorum longus muscles following 7 days recovery from TK-induced I/R (B).  


































































Figure 3.6. Representative Western blots and quantitative values of Akt, mTOR, and 
FoxO3 phosphorylation in the gastrocnemius muscle of 6 mo (young) and 24-27 mo (old) 
C57BL/6 mice following 1, 3, 5, and 7 days of recovery from 2 hour TK-induced I/R.  
Coomassie blue (CB)-stained polyacrylamide gel demonstrates that equal loading 
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Chapter IV:  Controlled Release of IGF-I from a Biodegradable Matrix 
Improves Functional Recovery of Skeletal Muscle from Ischemia/Reperfusion 
 
ABSTRACT 
 Ischemia/reperfusion (I/R) injury is a considerable insult to skeletal muscle, often 
resulting in prolonged functional deficits.  In the current study we evaluated the 
controlled release of insulin-like growth factor-I (IGF-I), from a biodegradable 
PEGylated fibrin gel matrix and the subsequent recovery of skeletal muscle from I/R.  
The hind limbs of male Sprague-Dawley rats were subjected to 2 hour tourniquet (TK)-
induced I/R then treated with saline, bolus IGF-I (bIGF), PEGylated fibrin gel (PEG-Fib), 
or IGF-I conjugated PEGylated fibrin gel (PEG-Fib-IGF).  Functional and histological 
evaluations were performed at 14 days of reperfusion, and muscles from 4-day animals 
were analyzed by Western blotting and histological assessments.  There was no 
difference in functional recovery between saline, bIGF, or PEG-Fib groups.  However, 
PEG-Fib-IGF treatment resulted in significant improvement of muscle function and 
structure.  Activation of the PI3K/Akt pathway was significantly elevated in PEG-Fib-
IGF muscles, compared to PEG-Fib treatment, at 4 days of reperfusion, suggesting 
involvement of this pathway as a mediator of improvement.  Increases in myoblast 
activity was not evident as a result of PEG-Fib-IGF treatment.  Taken together, these data 
give evidence for a protective role for the delivered IGF.  These results indicate PEG-Fib-
IGF is a viable therapeutic technique in the treatment of skeletal muscle I/R injury. 
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INTRODUCTION 
Ischemia/reperfusion (I/R) injury is a considerable perturbation to the extremities, 
often occurring in instances of vascular surgeries, orthopedic surgeries, or tourniquet 
(TK) use [65, 97].  The ischemic phase of I/R includes the accumulation of metabolites 
and depletion of ATP, while the more detrimental reperfusion phase is characterized 
largely by a burst of free radicals, causing severe damage to affected cell membranes, that 
can ultimately lead to apoptosis and/or necrosis [65, 98].  
Histopathology and large functional deficits persist in the skeletal muscle of 
rodents following TK-induced I/R [26, 69].  In response to I/R, local upregulation of the 
pro-regenerative growth factor, insulin-like growth factor-I (IGF-I) occurs [26, 41, 50].  
The actions of IGF-I following muscle injury include the stimulation of myoblast 
proliferation, promotion of myoblast differentiation, and improved survival of affected 
cells [1, 38].    Over-expression of IGF-I does facilitate skeletal muscle recovery 
following cardiotoxin-induced injury [4], therefore we hypothesized that increasing the 
local concentration of IGF-I would be a potential therapeutic method for the treatment of 
skeletal muscle I/R.  Since the beneficial effects of IGF-I are mediated largely by the 
Ras/Raf-1/ERK MAP kinase and PI3K/Akt pathways [1], we also hypothesized that one 
or both of these pathways must be involved in any measurable IGF-I mediated 
improvements in muscle recovery.  
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The controlled release of growth factors from an intramuscular (IM), 
biodegradable matrix over time is an attractive alternative to multiple bolus injections of 
growth factor, and is more clinically feasible than genetic over-expression treatments.  In 
previous experiments, a polyethylene glycol (PEG)-ylated fibrin gel (PEG-Fib) matrix 
containing covalently-bound growth factor has effectively improved left ventricular 
function following myocardial infarction [99, 100].  Following injection and subsequent 
polymerization, the covalently-bound growth factor is released from the PEG-Fib matrix 
into the local environment as degradation occurs, thereby allowing for the controlled 
release of growth factor from a single injection.  This property makes PEG-Fib an 
attractive tool for growth factor therapy following muscular injuries. 
In the present study, we tested our hypothesis that PEG-Fib-mediated delivery of 
IGF-I will improve the functional recovery of skeletal muscle following I/R.  A bi-
functional succinimidylglutarate PEG (SG-PEG-SG) was used to successfully conjugate 
fibrinogen and IGF-I, leading to a matrix that releases supra-physiological amounts ( >10 
ng/mL) of IGF-I out to at least 4 days, in vitro.  The PEG-Fib-IGF matrix was utilized as 
an IM-delivered treatment for TK-induced I/R of skeletal muscle.  Functional and 
histological evaluations were performed following 14 days of reperfusion.  Four day 




Male Sprague-Dawley rats (6-9 mo; Charles River) were used for this study.  Rats 
were housed individually, maintained on a 12-hour light/dark cycle, and were allowed ad 
libitum access to food and water.  All experimental procedures were approved and 
conducted in accordance with guidelines set by the University of Texas at Austin 
Institutional Animal Care and Use Committee. 
Tourniquet Application 
The 2 hour TK-induced I/R reperfusion model of muscle injury was performed as 
previously described [26].  Briefly, a single, randomly-selected hind limb was elevated, 
and a pneumatic TK (Hokanson) was placed proximal to the knee.  The TK was inflated 
to 250 mm Hg using the Portable Tourniquet System (Delfi Medical Innovations) for a 2-
hour duration.  During the course of this procedure, rats were anaesthetized with 2% 
isoflurane, and body heat was maintained with the use of a heat lamp. 
PEGylated Fibrin Gel Delivery of IGF-I 
Growth factor conjugated PEGylated fibrin gel was prepared essentially as 
previously described [99-101].  Briefly, bifunctional SG-PEG-SG (NOF America Corp) 
was reacted with reconstituted porcine fibrinogen (Sigma; 5:1 PEG:fibrinogen molar 
ratio; pH 7.8) and hIGF-I (Peprotech).  Polymerization was induced by the addition of 25 
U/mL hThrombin (Sigma).  The final concentrations of fibrinogen and IGF-I were 10 
mg/mL and 25 µg/mL, respectively. 
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Twenty-four hours following release of the TK, 0.25 mL of either sterile PBS 
(saline; n = 8), bolus IGF-I (bIGF; 25 µg/mL; n = 4) empty PEGylated fibrin gel (PEG-
Fib; n = 6), or IGF-I conjugated PEGylated fibrin gel (PEG-Fib-IGF; n = 6) was injected 
into the lateral gastrocnemius (LGAS) muscle of the TK-injured limb.  PEG-Fib and 
PEG-Fib-IGF treatments were injected as a fluid and polymerized in situ.  Functional 
assessments were performed at 14 days of reperfusion. 
In a subsequent experiment aimed at investigating potential mechanisms behind 
PEG-Fib-IGF-mediated improvements, 0.25 mL of PEG-Fib (n = 4) or PEG-Fib-IGF (n = 
4) was injected in the same manner, while animals were allowed 4 days of reperfusion.  
LGAS muscles were harvested from euthanized animals, embedded in OCT compound, 
frozen in liquid nitrogen-cooled isopentane, and stored at -80 ºC until further analysis. 
Functional Assessment 
Following 14 days of reperfusion, evaluation of LGAS force production in situ 
was performed as previously described [102].  Briefly, the GAS muscle was isolated 
from all other muscles in anaesthetized rats, innervation to the medial GAS was removed, 
and the Achilles tendon was secured to the lever arm of a dual-mode servomotor (Aurora 
Scientific Model 310B).  The muscle was activated using a stimulator (A-M Systems 
Model 2100) with electrodes applied to the tibial nerve.  Optimal length (Lo) was 
determined by finding the length producing the maximal twitch force.  Maximal peak 
tetanic tension (Po) was measured at Lo at a frequency of 150 Hz and the minimal 
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voltage required to elicit a maximal response.  Each contraction was followed by 2 
minutes of rest.  Muscle temperature was maintained with a heat lamp and mineral oil.  
Data were stored and analyzed using LabView software.  After the completion of 
contractile measurements, the muscles were dissected free, weighed, embedded in OCT 
compound, frozen in liquid nitrogen-cooled isopentane, and stored at -80 ºC until further 
analysis.  LGAS measurements of non-injured limbs were used for a non-TK control 
values (n = 14). 
Histology and Immunohistochemistry 
 Frozen, OCT-embedded muscle samples from  4 and 14 reperfusion groups were 
sectioned on a cryostat (Leica CM1900), and prepared on a slide.  Hematoxylin & eosin 
(H&E) staining was performed, as previously described [102], and slides were observed 
with a light microscope (Nikon Diaphot) with the 20X objective lens.  Images were taken 
using a mounted digital camera (Optronix Microfire).  Myofiber cross-sectional area 
(CSA) was measured by outlining using ImageJ software (250-600 fibers/group).   
Immunohistochemistry (IHC) was performed as previously described [102].  
Slides were blocked with 5% normal donkey serum and 1% BSA in PBS, and stained 
with anti-desmin (1:200; Santa Cruz), anti-neonatal myosin heavy chain (1:200; Santa 
Cruz), anti-myogenin (1:200; Santa Cruz), or anti-MyoD (1:200; Santa Cruz) antibodies.  
Sections were detected with donkey anti-goat IgG-FITC fluorescein (1:100; Santa Cruz), 
donkey anti-rabbit-FITC fluorescein (1:100; Santa Cruz) or a donkey anti-mouse IgG-
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TRITC fluorescein (1:100; Santa Cruz) and counter-stained with DAPI.  
Immunofluorescence was visualized with a Leica DM LB2 fluorescence microscope with 
the 20X objective lens and photographed with a Leica DFC340FX digital camera.  For 
quantification, the total number of nuclei co-expressing DAPI and either MyoD or 
myogenin were counted using ImageJ and expressed as a percentage of total nuclei 
present in the image area.  The number of intact myofibers expressing desmin or neonatal 
myosin heavy chain was counted using ImageJ and expressed as a percentage of the total 
number of myofibers in the image area.  For each measure, 3 fields of view were 
evaluated from 3 muscles per group. 
Western Blotting 
Western blotting was performed as previously described [26] using anti-IGF-I 
(Peprotech), anti-pAkt1/2/3 (Ser 473; Santa Cruz Biotechnology), anti-Akt (Cell 
Signaling), anti-pmTOR (Ser 2448; Cell Signaling), anti-mTOR (Cell Signaling), anti-p-
p70S6K (Thr 389; Santa Cruz Biotechnology), anti-p70S6K (Cell Signaling), and anti-
MuRF-1 (ECM Biosciences) antibodies.  The membrane was stripped of 
phosphorylation-specific antibodies and was re-probed with total protein antibodies.  
Values were quantified relative to those of the PEG-Fib control group.  Coomassie blue 
staining (Bio-Rad) was performed to verify equal loading. 
ELISA 
 40 
IGF-I release kinetics were performed similar to that previously described [100] 
using the hIGF-I Quantikine ELISA kit (R&D Systems).  Procedures were followed as 
directed by the manufacturer’s instructions.  Release kinetics were quantified as percent 
of total IGF-I released from the matrix.   
Statistical Analysis 
Functional assessments and IHC values were analyzed using an appropriate form 
of ANOVA (Tukey post-hoc test; α = 0.05), and Western blotting data were analyzed 
using Student’s T-test (α = 0.05).  All values are represented as the mean ± SEM, unless 
noted otherwise. 
RESULTS AND DISCUSSION 
Genetic over-expression studies have demonstrated that IGF-I does facilitate 
muscle regeneration following traumatic injury [4], thus making it a promising molecule 
to be utilized therapeutically for the treatment of muscle injuries.  However, its short half-
life (10 – 30 min) and potentially negative systemic effects has limited the molecule’s 
therapeutic application.  The purpose of this study was to evaluate the therapeutic 
potential of delivering IGF-I in a controlled manner, using an intramuscular PEG-Fib 
platform, in the treatment of skeletal muscle I/R. 
Conjugation and release of IGF-I from PEGylated fibrin gel 
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 Because covalent bonding of PEG to both fibrinogen and growth factor is 
essential to achieve controlled release when using the PEG-Fib delivery system (Figure 
4.1), we first had to verify the formation of fibrinogen-PEG-IGF-I complexes.  
Simultaneous incubation of fibrinogen, SG-PEG-SG, and IGF-I resulted in the formation 
of large IGF-I immunoreactive complexes, as determined by Western blotting (Figure 
4.2A).  This covalent bonding occurs when each SG functional group on the PEG 
molecule reacts with a free amine on a neighboring protein.  Release kinetics of IGF-I 
from the PEG-Fib matrix was measured in sequential release samples using ELISA.  
Though the majority of IGF-I is released from the matrix with the first 24 hours (Figure 
4.2B), a physiologically relevant dose of ~12 ng/mL [103, 104] was measured at 96 hours 
(Table 4.1).  This early release is likely due to the low molecular weight of IGF-I (~7.5 
kDa), which limits the number of free amine groups required for reaction with SG-PEG-
SG.  For example, the slightly larger SDF-1α (~11 kDa) is progressively released across 
7 days from PEG-Fib [100].  IGF-I immunoreactivity in the release samples was also 
analyzed by Western blotting to demonstrate that IGF-I was mostly released as free 
peptides, rather than large complexes that may have impaired bioactivity (Figure 4.2B 
bottom). 
PEGylated fibrin gel delivery of IGF-I improves recovery of muscle 
 The specific aim of the current study was to determine the efficacy of PEG-Fib-
IGF treatment in improving the functional recovery of skeletal muscle from I/R.  To 
accomplish this, an IM injection of saline, bIGF, PEG-Fib, or PEG-Fib-IGF treatment 
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was administered to the LGAS 24 hours after TK release.  Functional evaluations of the 
LGAS were performed after 14 days of reperfusion.  We observed no difference in 
functional recovery with saline, bIGF, or PEG-Fib treatments (Figure 4.3).  PEG-Fib-
IGF treatment, however, resulted in substantial recovery of force, compared to saline 
treatment (19.2±1.0 N vs. 12.4±0.6 N; p < 0.05).  This improvement is dependent on an 
improvement in specific tension of the muscle, rather than just changes in muscle mass 
(Table 4.2).  Interestingly, there were no significant differences in muscle mass or cross-
sectional area between the groups, however both control and PEG-Fib-IGF groups 
strongly trended towards higher values in both parameters than other groups.  This lack 
of statistical difference is likely due to large variations from persisting inflammation 
and/or edema in groups demonstrating more histological pathology (saline, bIGF, and 
PEG-Fib) [26, 105].  These results indicate the PEG-Fib-IGF treatment has therapeutic 
potential for skeletal muscle I/R, achieving comparable results to recovery in muscle-
specific IGF-I overexpression models [4].  The lack of benefit from a single bolus 
injection of IGF-I agrees with the results of previous studies [106], and highlights the 
importance of covalent bonding of IGF-I to the matrix in order to prolong release and 
protect the IGF-I molecule from rapid degradation.   
 Histological evaluations of H&E stained LGAS cross-sections were also 
performed at the 14-day reperfusion time point (Figure 4.4).  Saline-treated muscle 
displayed the typical abundance of small myofibers containing central nuclei seen in 
skeletal muscle following I/R, which is evidence of substantial degeneration/regeneration 
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cycling of injured myofibers.  The presence of large myofibers of round morphology in 
these samples is indicative of focal edema and/or myofiber hypercontraction, which are 
both hallmarks of muscle pathology.  Bolus IGF-I treated muscle displayed similar 
characteristics as saline treatment in terms of histological pathology and left-skewing of 
distribution of myofiber size.  Treating I/R-affected muscles with PEG-Fib alone resulted 
in modest improvements in the histological morphology and myofiber distribution of the 
LGAS.  This superficial improvement is not surprising, as PEG-Fib strongly binds many 
important growth factors, including transforming growth factor-β (TGFβ) [107-109], 
fibroblast growth factors (FGFs) [110, 111], and vascular endothelial growth factor 
(VEGF) [112].  Muscles treated with PEG-Fib-IGF displayed almost no signs of 
pathology and demonstrated a myofiber size distribution comparable to that of control 
muscle.  In addition, the distribution of muscle fibers < 2000 µm2 in size was quantified 
(Figure 4.5), revealing that PEG-Fib-IGF treatment resulted in significantly less small 
fibers than other treatment groups and was no different than control muscle.  These data 
indicate improvements in histological morphology accompany the improved functional 
recovery of skeletal muscle from I/R using PEG-Fib-IGF as a treatment strategy. 
 To accompany our data depicting improved recovery following PEG-Fib-IGF 
treatment, IHC staining for desmin, neonatal myosin heavy chain (nMHC), and myogenin 
was performed in saline, PEG-Fib, and PEG-Fib-IGF groups (Figure 4.6).  Desmin is a 
sarcomere-associated protein whose immunoreactivity is rapidly lost in perturbed 
myofibers [105].  We found a significantly higher incidence of desmin-positive 
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myofibers in PEG-Fib-IGF treated muscles than in saline or PEG-Fib groups, which is in 
agreement with our H&E depiction of healthier muscle following PEG-Fib-IGF 
treatment.  In addition, we looked at immunoreactivity of nMHC, an immature myosin 
heavy chain isoform that is found in actively regenerating muscle [113], and nuclear 
expression of myogenin, a muscle regulatory factor (MRF; muscle specific transcription 
factor) expressed in the later stages of myogenesis [39], as indicators of active muscle 
regeneration.  PEG-Fib-IGF treatment resulted in significantly less nMHC-positive fibers 
than both saline and PEG-Fib groups, and significantly less myogenin-positive nuclei 
than saline treatment.  These results suggest that the myogenic/regenerative program is 
near completion in PEG-Fib-IGF treated muscles following 14 days of reperfusion, yet is 
still prominent in saline and PEG-Fib treatment groups.  Taken together, our data indicate 
that PEG-Fib-IGF mediated therapy hastens both the histological and functional recovery 
of skeletal muscle from I/R injury, compared to all other tested groups. 
Hyperactivation of the PI3K/Akt pathway may mediate therapeutic effect 
From the data demonstrating PEG-Fib-IGF-mediated improvement in muscle 
recovery from I/R, we gathered that 2 potential mechanisms are responsible for our 
results:  1) PEG-Fib-IGF is facilitating the regenerative actions of myoblasts, thereby 
speeding up the regenerative time frame, or 2) PEG-Fib-IGF exerts a protective effect on 
the existing myofibers, thus resulting in less damage from the I/R insult.  We therefore 
repeated PEG-Fib (control) and PEG-Fib-IGF treatment groups with only 4 days of 
reperfusion to discern which mechanism is likely behind the beneficial effect of PEG-
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Fib-IGF treatment.  The 4-day reperfusion period was chosen because an appreciable 
amount of IGF-I is still being released from PEG-Fib-IGF (Table 4.1) and it is a time 
point of maximum myoblast proliferation [23, 114].   
The canonical intracellular signaling induced by activation of the IGF-IR in 
skeletal muscle includes the Ras/Raf-1/ERK MAP kinase and PI3K/Akt pathways [1].  
Activation of the ERK pathway is generally associated with induction of myoblast 
proliferation [103], while activation of the PI3K/Akt pathway results in diverse effects, 
including activation of protein synthesis, abrogation of catabolism, promotion of cell 
survival, and stimulation of myoblast differentiation [103, 115].  To investigate if either 
of these pathways are differentially expressed between PEG-Fib and PEG-Fib-IGF 
treated muscles, LGAS muscles were harvested after 4 days of reperfusion and analyzed 
by Western blotting for phosphorylation of ERK and Akt. Phosphorylation of ERK was 
not different between the 2 treatments, however, p-Akt of the PEG-Fib-IGF treatment 
demonstrated an ~2-fold increase in content over PEG-Fib treated muscles (Figure 4.7).  
IGF-I-induced activation of Akt promotes protein synthesis, which is regulated through 
the activation of mTOR and p70S6K [116], and negatively regulates muscle atrophy by 
preventing the expression muscle-specific E3 ubiquitin ligases (components of the 
ubiquitin-proteasome system) through inactivation of FoxO transcription factors [117, 
118].  PEG-Fib-IGF treatment also resulted in similar increases in mTOR and p70S6K 
phosphorylation as those found for Akt, as well as vastly reduced levels of MuRF-1, a 
cytosolic E3 ubiquitin ligase implicated with sarcomere degradation [119, 120], 
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demonstrating hyper-activation of the PI3K/Akt pathway is a feature of PEG-Fib-IGF 
treatment.  
Activation of Akt has been shown to protect cells from apoptotic and/or necrotic 
fates in a number of models and tissues [95, 121-123].  In agreement with this, H&E 
staining revealed dramatically reduced signs of muscle pathology following PEG-Fib-
IGF treatment (Figure 4.8 top), compared to PEG-Fib treatment, suggesting a lower 
magnitude of initial muscle injury corresponds with the increased Akt activation.  
Unexpectedly, we could not detect any difference in frequency of MyoD (Figure 4.8 
bottom), an early expressed MRF, or myogenin (data not shown) positive nuclei, 
therefore enhanced activation of myoblasts does not appear to be a mechanism of the 
improved recovery with PEG-Fib-IGF treatment.  These results in conjunction with the 
signaling data suggest PEG-Fib-IGF treatment improves muscle recovery from I/R by 
promoting hyper-activation of the PI3K/Akt pathway, thereby limiting the extent of cell 
death and degeneration that typically accompanies the I/R perturbation.  In agreement 
with this, previous studies in our research group have demonstrated reduced activation of 
this pathway correlates with a reduction in functional recovery in aged rats from TK-
induced I/R [26].  To verify this conclusion, however, future investigations to thoroughly 




 I/R injury is a considerable perturbation to skeletal muscle, often resulting in 
substantial and prolonged functional deficits.  In the current report, we have demonstrated 
that the sustained release of IGF-I from an IM, biodegradable PEGylated fibrin gel matrix 
significantly improves the functional recovery of skeletal muscle from TK-induced I/R.  
We also identify activation of the PI3K/Akt pathway, and not enhanced myoblast 
activity, as a potential mechanism mediating this beneficial effect.  The results of this 
study may lead to future investigations to test the effectiveness of PEG-Fib-IGF treatment 
in other models of muscle injury, including crush injuries and lacerations.   
This particular form of growth factor is distinct from purely synthetic polymer delivery 
systems in the form of monolith devices, foams, or particles in that the material is both 
injectable and can retain the delivered agent to the site of injury [124].  Since both fibrin-
based and PEG-containing products are currently FDA approved, the translation of this 
form of therapy into the clinical realm is realistic.  Additional directions may include the 
delivery of growth factor combinations to optimize tissue and/or incorporation of stem 
cells to facilitate the regenerative process of damaged tissue.  For example, vasculogenic 
factors, such as VEGF or HGF, can possibly be used in this system to improve vascular 







Table 4.1. IGF-I release from PEGylated fibrin matrix 

































Uninjured 1689±47 1.35±0.04 19.6±0.5 
Saline 1461±55 1.20±0.04 10.5±0.8* 
Bolus IGF-I 1491±112 1.18±0.10 10.5±0.7* 
PEG-Fib 1522±93 1.12±0.07 11.7±1.0* 
PEG-Fib-IGF 1643±75 1.30±0.06 14.8±0.6*,# 
LGAS = lateral gastrocnemius; CSA = cross-sectional area; SPo = specific 
tension.  Values indicated are mean±SEM.  * p < 0.05 vs. Uninjured, # p < 
0.05 vs. Saline, bolus IGF-I, and PEG-Fib groups. 
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Figure 4.1. Generation of growth factor-conjugated PEGylated fibrin gel (PEG-Fib-GF) is 
achieved by the co-incubation of fibrinogen, bi-functional polyethylene glycol (PEG), 
and growth factor.  The result is a mixture of various covalently linked products 
composed of the original components.  This mixture is polymerized by the addition of 











Figure 4.2. Covalent conjugation of IGF-I to PEGylated fibrinogen is verified by Western 
blotting using an anti-IGF-I antibody (A).  Release kinetics of IGF-I from the PEGylated 
fibrin gel delivery system (B top) was determined by ELISA.  Western blotting confirms 
that the majority of immunoreactive IGF-I released from PEGylated fibrin gel is 
consistent that with of IGF-I peptide (B bottom), rather than large complexes.  Values 
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Figure 4.3. After 14 days of reperfusion, maximum force production of the lateral 
gastrocnemius (LGAS) was measured in situ from the following treatment groups:  
saline, bolus IGF-I, PEGylated fibrin gel (PEG-Fib), and IGF-I conjugated PEG-Fib 
(PEG-Fib-IGF). Values represented are the mean ± SEM; *p < 0.05 vs. uninjured, #p < 









































Figure 4.4. H&E stained sections were prepared (left) and evaluated for fiber size 
































































































































Figure 4.5. Proportions of small muscle fibers (< 2000 µm2) were compared among the 
different treatment groups.  Values represented are the mean ± SEM; *p < 0.05 vs. 









































Figure 4.6. Immunohistochemistry for desmin, neonatal myosin heavy chain (nMHC), 
and myogenin was performed on the lateral gastrocnemius muscles from saline, 
PEGylated fibrin gel (PEG-Fib), and IGF-I conjugated PEG-Fib (PEG-Fib-IGF) groups 
following 14 days of reperfusion.  Representative slides and marker-specific 
quantifications are provided.  Values represented are the mean ± SEM; *p < 0.05 vs. 








Figure 4.7. Western blotting was performed on PEGylated fibrin gel (PEG-Fib) and IGF-I 
conjugated PEG-Fib (PEG-Fib-IGF) treated lateral gastrocnemius muscles following 4 
days of reperfusion.  Proteins assessed include the phosphorylated and total protein forms 
of ERK, Akt, mTOR, and p70S6K, as well as the E3 ubiquitin ligase MuRF-1.  Values 














































Figure 4.8. H&E staining and immunohistochemistry for the myoblast marker MyoD 
were performed on PEGylated fibrin gel (PEG-Fib) and IGF-I conjugated PEG-Fib 



















Chapter V:  Evaluation of Ischemia/Reperfusion induced  






 The presence of macrophages (MPs) is essential for skeletal muscle to properly 
regenerate following injury.  The purpose of this study was to develop simple model for 
the evaluation of MP profiles in injured muscle to facilitate the understanding of the 
complex post-injury environment.  Using flow cytometry, we identified 3 distinct 
CD11b+ cell populations that differ in expression of Ly-6C and F4/80.  This model was 
utilized for the analysis of muscle-specific MP patterns and evaluation of 
immunomodulation by fibrin-based treatments following hind limb ischemia/reperfusion 
(I/R) injury.  Furthermore, we demonstrate that the Ly-6Clo F4/80+ population of MPs 








Macrophages (MPs) are an essential part of the muscle regenerative process, as 
demonstrated through numerous studies where their post-injury infiltration has been 
perturbed [14, 54-56, 59, 125].  The recently emerging paradigm of MP infiltration of 
entails immature monocytes expressing high levels of Ly-6C migrating into damaged 
tissue [13].  These cells differentiate into inflammatory MPs that partake in phagocytosis 
of necrotic debris, then switch to an anti-inflammatory phenotype to aid in the myogenic 
repair process [14].  This phagocytosis-induced phenotype shift appears to be a CREB-
dependent process [126], and is likely due to phosphatidylserine ingestion [127]. 
Of particular interest to our research group, much evidence suggests that MPs are 
required for the robust post-injury upregulation of IGF-I, as severely reduced IGF-I 
expression has been reported with chlodronate-depletion [56] and CCR2/CCL2 
disruption [59, 125].  Frenette et al [128] revealed that MPs are required for IGF-I 
expression in myoblast co-cultures.  In addition, Lu et al [59] demonstrate that IGF-I is 
highly expressed in both the Ly-6Chi and Ly-6Clo subsets of F4/80+ cells, with more being 
expressed in the latter.  This evidence strongly suggests that MPs are the primary cellular 
source of IGF-I in regenerating skeletal muscle. Therefore, conditions resulting in 
impaired IGF-I expression following injury, such as aging [26, 50], may very well be 
caused by a MP impairment.  In agreement with this, elderly humans exhibit altered post-
exercise MP profiles [129], and aged rodents have lower leukocyte mobilization and 
infiltration following myocardial ischemia/reperfusion [130, 131].  Furthermore, a mouse 
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diabetic model, the db/db mouse, shows reduced regeneration and lower MP numbers 
following cardiotoxin injury [132].   
The purpose of the present study was to develop a simple method for the 
evaluation of inflammatory cells in injured skeletal muscle.  With a tri-color flow 
cytometric analysis, we identified 2 distinct mouse CD11b MP populations that differ in 
relative expression of F4/80 and Ly-6C in I/R affected hind limb muscles.  Using this 
analysis, we revealed that intramuscular fibrinogen-based therapies increase macrophage 
prevalence in injured muscle, which may account for notable histological improvements 
our group has reported [133]. In agreement with this, FACS isolation and subsequent 
intramuscular injection of the Ly-6Clo F4/80+ population improved functional recovery of 
muscle from I/R.   
 METHODS AND MATERIALS 
Animals 
 Male C57BL/6 mice (~6 mo) were used for this study.  Animals were housed 
individually with ad libitum access to food and water, and maintained on a 12-hour 
light/dark cycle.  All experimental procedures were approved and conducted in 
accordance with the guidelines set by The University of Texas at Austin IACUC. 
Tourniquet Application 
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Mice were anesthetized with 2% isoflurane gas prior to and for the duration of 
tourniquet application.  A single, randomly selected hind limb was elevated, and a 
pneumatic tourniquet (D.E. Hokanson, Inc.) was wrapped snuggly against the proximal 
portion of the limb and inflated to 250 mm Hg by the Portable Tourniquet System (Delfi 
Medical Innovations Inc.) to ensure complete occlusion of blood flow to the limb for a 
duration of 2 hours [69].  Body temperature was maintained at 37±1º C with the use of a 
heat lamp during this procedure.  After 2 hours, the pneumatic tourniquet was removed, 
and the mouse was returned to its cage for recovery.   
PEGylated fibrin gel injection 
Following 24 hours of reperfusion, 100 uL of saline, empty PEGylated fibrin gel 
(PEG-Fib), or IGF-I conjugated PEG-Fib (PEG-Fib-IGF), described previously [133], 
was injected into the gastrocnemius muscles of the TK-affected limb (50 uL into each 
head).  Briefly, human fibrinogen (Sigma) was allowed to react with SG-PEG-SG (NOF 
America) and human IGF-I (Peprotech) to generate covalently-linked products.  Gel 
polymerization was initiated by the addition of human thrombin (Sigma; 25 U/ml).  The 
final concentration of components was 10 mg/mL fibrinogen, 0.5 mg/mL SG-PEG-SG, 
and 25 ug/mL IGF-I.  
Macrophage Isolation and Flow Cytometry 
 Tibialis anterior (TA) and lateral gastrocnemius (LG) muscles were harvested 
from euthanized mice, finely minced with scissors, and incubated for 40 minutes in 10 
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volumes/muscle weight of 1% collagenase II (Invitrogen) dissolved in DMEM at 37 C.  
Samples were filtered through 40 um nylon cell strainers (BD), and prepared for flow 
cytometry using PE-conjugated anti-CD11b (BD), FITC-conjugated anti-Ly6C 
(Biolegend), and APC-conjugated anti-F4/80 (Biolegend).  Appropriate isotype controls 
were also used to verify specificity of staining.  Samples were run on the BD Fortessa 
Flow Cytometer at the University of Texas Institute of Cell and Molecular Biology core 
facility.  Fluorescence activated cell sorting (FACS) was performed using the BD 
FACSAria.  Data were analyzed using Flowing Software 2. 
Force Measurements 
Gastrocnemius muscles were surgically isolated from all other muscles and 
connective tissue, and subjected to functional measurements.  The Achilles tendon was 
secured to the muscle lever arm of a servomotor (model 305B, Cambridge Technologies) 
interfaced with a computer equipped with an A/D board (National Instruments).  The 
muscle was stimulated to contract using an Isolated Pulse Stimulator (Model 2100; A-M 
Systems) with leads applied to the sciatic nerve.  Muscle temperature was kept constant 
at 37º C with warm mineral oil and a radiant heat lamp throughout the procedure.  
Optimal length of the muscle was determined by measuring maximal twitch tension at a 
stimulation of 0.5 Hz.  At optimal length, the muscle was stimulated at 150 Hz for 350 
ms to elicit the peak tetanic tension (Po), and was allowed 2 minutes of rest between each 




Slides of paraffin-embedded gastrocnemius muscles were prepared.  Hematoxylin 
& eosin (H&E) staining was performed, as previously described [102], and slides were 
observed with a light microscope (Nikon Diaphot) with the 20X objective lens.  Images 
were taken using a mounted digital camera (Optronix Microfire). 
Statistical Analysis 
Data were analyzed using Student’s T-tests or ANOVA, where appropriate (α = 
0.05).  Values are represented as mean ± SEM.  
RESULTS 
Macrophage profile characterization 
The investigation of inflammatory cell profiles in injured skeletal muscle by flow 
cytometric techniques varies by lab, and often involves costly purification techniques, a 
large array of labeling antibodies, and/or the use of novel transgenic animals to 
label/modify specific cell populations.  To provide a rapid and cost-effective, yet reliable, 
method of inflammatory profile analysis, freshly isolated cells from I/R-injured muscles 
were labeled with fluorochrome-conjugated anti-CD11b, expressed by monocyte lineage 
cells and neutrophils, anti-Ly6C, a surface marker highly expressed on inflammatory 
monocytes/MPs and neutrophils, and anti-F4/80, a marker associated with mature MPs.  
Analysis of CD11b+ cells reveals 3 distinct subpopulations of cells that vary in 
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expression of Ly-6C and F4/80 (Figure 5.1A).  This includes a population of F4/80- Ly-
6Cmid cells [quadrant 1 (Q1)] , which are likely neutrophils, a F4/80+ Ly6Chi population 
(Q4), which appear to be early infiltrating, inflammatory MPs, and F4/80+ Ly-6Clo cells 
(Q2) representing mature, pro-regenerative MPs [14].  In agreement, each population 
demonstrates appropriate profiles in side-scatter (SSC) vs. forward-scatter (FSC) plots 
(Figure 5.1B). 
Muscle-specific MP profiles following I/R 
First experimental utility of this technique was to investigate differential immune 
profiles of lateral gastrocnemius (LG) and tibialis anterior (TA) muscles following I/R.  
Following reperfusion, both muscles have roughly equivalent proportions of Q1, Q2, and 
Q4 cells (Figure 5.2A).  CD11b+ cells were barely detectable in control muscle, and 
resided mostly in Q2 (Figure 5.2B).  Cell populations were quantified relative to 3 day 
LG CD11b+ cells (3.28x104 cells/mg muscle), revealing that TA muscles contain a 
significantly higher number of CD11b+, Q2, and Q4 cells at 3 days of reperfusion 
(Figure 5.2C).  This difference was gone by day 5.  These results indicate that muscle-
specific immune profiles occur following I/R injury, which may reflect differential 
susceptibility to damage or post-injury monocyte migration between the muscles.    
Immunomodulatory effects of PEGylated fibrin gel 
 In a previous study, our laboratory group reported that an intramuscular injection 
of IGF-I-conjugated PEGylated fibrin gel (PEG-Fib-IGF) drastically improved the 
recovery of skeletal muscle from I/R [133].  To investigate whether immunomodulation 
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occurs in PEG-based therapy, saline, PEG-Fib, or PEG-Fib-IGF was injected into the LG 
of mice following 24 hours of reperfusion, followed by MP profile evaluation for both 
the LG and TA in 3 and 5-day reperfusion groups (Figure 5.3).  At 3 days, there is a clear 
PEG-Fib effect on CD11b+ and Q2 cell numbers (52 and 65% increase, respectively), 
compared to saline, in the LG, though IGF-I appears to have no effect beyond PEG-Fib at 
this time.  Day 5, however, shows a clear IGF-I effect, as PEG-Fib-IGF treated LGs show 
a substantial 47 and 43% reduction in CD11b+ and Q2 cells, respectively compared to 
saline treatment.  In addition to revealing novel effects of PEG-based treatments, these 
data also demonstrate a clear disconnect between the MP accumulation (day 3) and 
persistence (day 5).  Interestingly, the non-treated TA muscles appear to mirror the 
relative MP composition of the treated LGs, suggesting PEG-Fib based treatments may 
have a whole limb effect in regards to MP prevalence. 
Increasing intramuscular MPs improves functional muscle recovery 
 The above-mentioned results suggest that increasing the number of MPs in a 
regenerating muscle may facilitate the recovery process.  To directly test this hypothesis,  
CD11b+ Ly-6Clo F4/80+ cells were isolated from 3 day reperfusion muscles using FACS, 
then injected (~1.5x106 cells) into day-matched gastrocnemius muscles.  Functional 
assessment at 14 days of reperfusion revealed significant improvements in maximum 
tetanic force production (2.2 N vs. 1.4 N), muscle mass (142 mg vs. 111 mg), and mass-
normalized force production (15.7 N/g vs. 12.4 N/g) in the MP treated group, compared 
to saline treated muscle.  This also translated to significantly improved recovery (in terms 
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of % of contralateral limb) of maximum force and muscle mass, while mass-normalized 
force demonstrated an obvious effect (Figure 5.4).  In agreement, MP-treated muscles 
display an improved histological appearance over saline treatment (Figure 5.5).  These 
data clearly show that increasing MP prevalence substantially improves skeletal muscle 
functional recovery from I/R, and suggests MP-based treatments may have therapeutic 
promise. 
DISCUSSION 
 The present study depicts a simple, reliable method for the investigation of MP 
profiles in injured skeletal muscle.  Given the absolute importance of MPs in the 
regenerative process, this provides a great tool in the investigations of conditions where 
skeletal muscle regeneration is impaired, such as aging [26, 50] and metabolic disorders 
[132].  In addition, we demonstrate that increasing MP prevalence by intramuscular 
injection of isolated MPs enhances muscle regeneration from I/R, suggesting novel, MP-
based therapies have potential for treatment of muscle injuries. 
 To investigate MP profiles in muscle injures, we analyzed CD11b+ 
subpopulations that differ in degree of Ly-6C and F4/80 expression. Using this method of 
analysis, we observed differences in MP abundance in the LG and TA following 3 days 
of reperfusion, suggesting that these 2 muscles may exhibit either different amounts of 
initial damage or different efficiencies of monocytes chemotaxis to the muscle.   
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We also identified that PEG-Fib (with or without IGF-I) increases MP 
accumulation at 3 days of reperfusion.  Interestingly, fibrinogen is a direct ligand for 
CD11b (an integrin receptor), resulting in migratory, phagocytotic, and cytokine 
expression changes [134].  This observation of PEG-Fib-induced increases in MPs could 
either be a result of increased infiltration, increased MP proliferation, or better MP 
survival.  These mechanistic details can be evaluated in vitro.  The substantial decrease in 
MP numbers with PEG-Fib-IGF at day 5 strongly suggests that MP persistence is 
independent of MP accumulation.  Since PEG-Fib-IGF appears to improve myofiber 
survival [133], a resulting sharp decline in intracellular leakage and/or amount of necrotic 
material is likely a major factor in MP persistence.  This IGF-I mediated effect on 
CD11b+ cell prevalence agrees well with those reported from muscle-specific IGF-I 
overexpressing mice following cardiotoxin injury [4].   
An incredibly interesting find detailed in this report is that FACS-isolated Ly-6Clo 
F4/80+ MPs greatly enhance functional muscle recovery from I/R upon intramuscular 
injection, indicating MP-mediated approaches represent a potential therapies for muscle 
injuries.  This MP-mediated improvement in recover could occur through a number of 
possible mechanisms, including an increase of local IGF-I [59], improved survival and/or 
activity of myoblasts [14, 135, 136], or facilitation of muscle remodeling [56, 58].  While 
our data is unique to skeletal muscle, similar therapies have been utilized to improve 
outcomes of myocardial infarction [137], sternal wounds [138], and skin ulcers [139-
142].  In fact, heterochronic MP transfer demonstrates that MPs from young donors can 
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hasten wound healing of old mice [143], suggesting MPs are perhaps the mediating factor 
in improved muscle regeneration of heterochronic muscle transplantation [27] and 
parabiosis [28] models.  This would be an exciting avenue to explore in future 
investigations. 
 The current report provides a simple method for the analysis of MP profiles in 
injured muscle, providing a great tool for the investigation of novel, immunological 
mechanisms involved in muscle regeneration.  In conjunction with immunomodulatory 
tactics, such as PEG-Fib, it is possible to investigate whether impaired regenerative 
situations, such as aging and metabolic disorders, are possibly a result of defective 
cellular infiltration or intrinsic deficits associated with MPs.  In doing so, it would also be 
possible to identify whether MP-derived IGF-I is the main effector responsible for 
regenerative defects found in such conditions, or if IGF-I expression is simply a surrogate 
that indicates MP levels.  We also provide strong evidence the MP-based therapies are 
effective for the treatment of muscle injuries, which may be more favorable than stem 
cell based therapy in situations where aberrant differentiation or long-term cellular 
persistence may be a concern.      
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Figure 5.1. Cells isolated from muscle following 3 days of reperfusion were labeled with 
PE-anti-CD11b, FITC-anti-Ly-6C, and APC-anti-F4/80 and subjected to flow cytometry.  
The CD11b+ population was further characterized by differential expression of Ly-6C 
and F4/80 (A), demonstrating 3 distinct subpopulations (Q1, Q2, Q4).  These 























Figure 5.2. Comparison of flow  CD11b+ cell profiles in lateral gastrocnemius (LG) and 
tibialis antierior (TA) muscles following 1 (n = 1), 3 (n = 5), and 5 days (n = 4) of 
reperfusion (A).  Control muscles demonstrate a very low number CD11b+ cells (B).  Cell 
population quantification (C) demonstrates muscle-specific numbers of CD11b+, Q2, and 
Q3 exist between the LG and TA.  Values are normalized to absolute number of CD11b+ 
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Figure 5.3. Relative cell quantification of 3 and 5-day reperfusion lateral gastrocnemius 
(LG) and tibialis anterior (TA) muscles treated with saline (n = 4), PEGylated fibrin gel 
(PF; n = 4), or IGF-I conjugated PF (PFI; n = 3-4).  Values are relative  to 3-day saline 


































































Figure 5.4. Maximum tetanic force production, muscle mass, and mass-normalized force 
production of the mouse gastrocnemius at 14 days of reperfusion following saline or 



































































Figure 5.5. Representative H&E slides of saline and macrophage-treated (Macs) 













Chapter VI:  General Discussion 
SUMMARY OF RESULTS 
1) Ischemia/reperfusion (I/R) injury of skeletal muscle results in robust upregulation 
of the IGF-I system.  This upregulation is greatly attenuated in aged skeletal 
muscle, and coincides with substantial regenerative defects.   
2) Sustained release of IGF-I from an intramuscular injection of PEGylated fibrin 
gel greatly improves functional recovery of skeletal muscle following I/R.  This 
therapeutic benefit is likely attributed to improved survival of affected myofibers. 
3) Flow cytometric analysis demonstrates 3 distinct subsets of CD11b+ cells are 
present in I/R-injured skeletal muscle.  These subpopulations differ in relative 
expression of Ly-6C and F4/80.  Isolation and intramuscular injection of the Ly-
6Clo F4/80+ population improves functional recovery of I/R-affected muscle, 
demonstrating that increases in MP prevalence can improve functional recovery 
of skeletal muscle. 
 
CONCLUSIONS 
In summary, the present body of work demonstrates that extrinsic factors in post-
injury intramuscular environment substantially affect the regeneration of the muscle. 
Specifically, we show that aging is characterized by impaired skeletal muscle 
regenerative capacity and exhibits attenuated post-injury IGF-I activity, sustained release 
 74 
of IGF-I from a biodegradable matrix greatly improves functional recovery of muscle 
from injury, and that macrophage prevalence in a damaged muscle can affect the 
functional recovery.  When put together in cohesive context with a specific condition in 
focus, such as sarcopenia, the approaches reported in this work provide the means to 
conduct insightful mechanistic work at the cellular and molecular levels, with at least two 
promising therapeutic modalities, IGF-I delivery via PEGylated fibrin gel and 
macrophage-based therapy, for the treatment of skeletal muscle injuries in individuals 
with regenerative impairments.     
 
FUTURE DIRECTIONS 
 This report provides the foundation for many different directions of future 
research.  Logically, it would be important to investigate whether an age-related decline 
in macrophage infiltration occurs, and whether this is the mechanism responsible for the 
attenuated IGF-I response.  Utilization of IGF-I delivery via PEGylated fibrin gel and/or 
macrophage-based therapies to treat injuries to sarcopenic muscle is also an avenue that 
should be pursued.  Indeed, similar approaches to characterize other conditions of 
impaired regeneration, such as metabolic disorders, would be incredibly fruitful.  Further 
refinement of macrophage-based therapies, such as differentiation of monocytes or 
hematopoietic stem cells, to provide adequate cell numbers would be necessary to 




Figure 6.1.  This schematic summarizes the results presented in the current work.  
Skeletal muscle injury results in both the upregulation of IGF-I and the infiltration of 
macrophages.  Both of these events positively affects muscle regeneration, while a 
decrease in IGF-I response, as shown with age, reduces muscle recovery.  It remains to be 
tested whether aging negatively affects macrophage infiltration and whether macrophages 








Appendix A:  Expanded Methods 
I. Tourniquet Application 
1.) Fill vaporizer with isoflurane (ISO). 
2.) Turn on oxygen tank to 1.5 L/min. 
3.) Pre-charge induction chamber for 5 min by turning ISO vaporizer up to 5%. 
4.) After precharging induction chamber, turn vaporizer down to 2 or 2.5%, and 
place rat in chamber. Monitor rat in chamber for 5 minutes.  
5.) Quickly remove rat and move to bed with nose cone. Make sure rat is under heat 
lamp, but at least 18 inches away from it. 
6.) Turn down vaporizer to 1.5 or 2%. 
7.) Shave one leg of rat on bed while in nose cone. 
8.) Wrap tape around foot of shaved leg. Hang the shaved leg with tape from clamp 
and leave for 5 minutes to drain excess blood from leg. 
9.) Place tourniquet (TK) tightly around leg as close to body as possible. 
10.) Once TK is tightly in place. Turn on PTS and set to 250 mmHg. Hold the 
TK’s into position on leg and inflate. 
11.) While rat is undergoing TK-induced ischemia, monitor respiration and 
maintain proper level of anesthetic. 
12.)   At appropriate time point deflate TK and place rat back in its home cage. 
 
II. Muscle Removal and Storage 
Solutions 
 0.9% NaCl solution (in dH2O) 
Procedure 
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1.) Prepare workstations for tissue harvest:  Pre-cut foil into appropriate number 
of ~2.5 inch squares and label appropriately; Suspend ~25 mL of isopentane 
in hanging freeze dish over a pool of liquid nitrogen; Add an appropriate 
amount of 0.9% NaCl solution to a weigh-boat. 
2.) Quickly excise muscles from animal and place in weigh-boat containing 0.9% 
NaCl.  If not dead already, sacrifice animal either by cutting femoral arteries 
or lethal injection of sodium pentabarbitol into heart. 
3.) Tare balance with a new weigh-boat, remove a single muscle from saline with 
forceps, blot off excess liquid on Kim wipes, and weigh muscle.  Record the 
weight into lab notebook. 
4.) Remove muscle from balance, place in cassette, and submerge it in liquid 
nitrogen-cooled isopentane.  Remove from isopentane, quickly remove 
muscle from cassette, wrap in appropriately labeled foil, and submerge in pool 
of liquid nitrogen. 
5.) Weigh and freeze remaining muscles similarly.  If balance does not return to 
zero following the removal of a muscle, re-tare the balance before weighing 
next muscle. 
6.) When finished with all samples, remove from liquid nitrogen pool, place in 
properly labeled box, and store at -80º C until further processing. 
7.) Dispose of weigh-boats, turn-off balance, pour isopentane back into original 
container (can be reused many times), pour liquid nitrogen back into original 
container, and prepare animal for proper disposal. 
 
III. Muscle Homogenization 
Solutions 
 1 M HEPES (pH 7.6; NaOH) 
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 5 M NaCl 
 10% Triton X-100 
 1 M β-glycerol phosphate 
 1 M NaF 
 100 mM PMSF 
(Store these at 4º C; may be made on prior date; check viability of chemical 
storage prior to use) 
Procedure 
1.) Prepare all stock solutions and store at 4º C.  Gather all materials needed; 
label all microcentrifuge tubes (you will need at least 5 for each sample) 
properly.  Begin icing dH2O, 50 mL conical tube, microcentrifuge tubes, 
homogenation tubes, Teflon pestals (or polytron rotor).  It is essential that all 
materials are kept as cold as possible throughout entire homogenization 
process. 
2.) Mix the pre-lysis buffer as indicated below: 
Pre-Lysis Buffer [Final] [Stock] For 50 mL 
50 mM HEPES (pH 7.6; NaOH) 1 M 2.5 mL 
150 mM NaCl 5 M 1.5 mL 
1% Triton X-100 10% 5.0 mL 
20 mM β-glycerol phosphate 0.5 M 1 mL 
10 mM NaF 1 M 0.5 mL 
dH20  32.5 mL 
*this solution can be mixed prior to day of homogenization 
 79 
Immediately before beginning homogenization, add the following ingredients: 
Protease Inhibitors (add fresh) [Stock] For 50 mL 
1 mM Na3VO4 10 mM 5 mL 
10 ng/mL Leupeptin 1 mg/mL 500 uL 
10 ng/mL Aprotinin 2 mg/mL 250 uL 
1:100 Phosphatase Inhibitor Cocktail 1  500 uL 
1:100 Phosphatase Inhibitor Cocktail 2  500 uL 
1 mM PMSF 100 mM 500 uL 
*Leupeptin must be mixed from powder form prior to addition 
This homogenization buffer is specific for determining phosphorylated states of 
proteins other goals may require alternative buffers.  Before homogenization 
procedure, calculate an estimated volume of buffer to be required.  If more than 
50 mL is required, prepare only 50 mL at a time.  Keep buffer on ice for duration 
of homogenization procedure. 
3.) Intstall either Teflon pestal in drill press or rotor to polytron; surround with 
ice.  Make sure all equipment is working. 
4.) Remove 3-4 muscle samples at a time from -80º C freezer and place in ice.   
5.) Remove 1 sample from ice, carefully remove foil, and excise ~200 mg of 
connective tissue-free muscle tissue sample.  Rewrap remaining muscle 
sample in foil and refreeze in liquid nitrogen. 
6.) Record weight of excised muscle in laboratory notebook, mince muscle with 
scissors, and transfer to cold homogenization tube.  Add homogenization 
buffer to muscle in a 15:1 volume to mass ratio (i.e. 0.2 g x 15 mL/g = 3 mL 
of buffer). 
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7.) Remove ice surrounding Teflon pestal or polytron rotor.  Keep 
homogenization tube surrounded by ice and carry to drill press or polytron. 
8.) For Teflon pestal:  Turn-on drill press, slowly raise homogenization tube until 
pestal reaches bottom of tube, then pull back down until suction is breached.  
After 5 passes, place tube back in ice to cool, then perform 5 more passes.  
Repeat this until all major portions of muscle are absent from homogenate.  
For polytron:  Raise homogenization tube until rotor is in contact with bottom 
of tube.  Turn-on polytron and set at desired speed for 10 seconds.  After 10 
seconds, turn-off polytron and place tube in ice.  Repeat if necessary. 
9.) Allow homogenate to sit in ice to let foam settle.  During this time wipe 
Teflon pestal with Kim wipe, or manually remove connective tissue from 
polytron rotor and run at high speed in clean, cold dH2O, then replace ice 
until next run.   
10.) Distribute homogenate evenly between 2 (more may be necessary) pre-
chilled, properly-labeled microcentrifuge tubes.  Aliquot 100 uL into a 3rd 
tube.  This portion will be used to determine total protein content of muscle, 
therefore can be stored at -80º C at this point.  Place all other tubes on ice. 
11.) Repeat starting at step 5 until all samples are homogenized, then repeat 
starting at step 4 until no more than 32 microcentrifuge tubes are prepared. 
12.) Make sure centrifuge is working properly, place samples into F-
20/MICRO centrifuge rotor head in a manner that keeps balance across the 
head, and secure the lid.  Set the rotor speed to 9650 rpm (12000g; RCF = 
0.00001118r N^2) and run for 30 minutes.  Make sure the temperature is at 4º 
C. 
13.) Remove centrifuged samples from head and return to ice.  Remove lipid 
layer with micropipette and dispose.  Carefully transfer supernatant into a 
clean, chilled, properly-labeled microcentrifuge tube, without disturbing the 
pellet. 
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14.) Store homogenates in a properly labeled container in -80º C freezer until 
further needed. 
 
IV. Protein Concentration Determination 
Solutions 
20% solution of Bio-Rad Protein Assay dye reagent (can be stored at 4º C for 2 
weeks) 
10 mg/mL BSA 
Procedure 
1.) Remove samples from -80º C freezer and place in ice to allow a slow thaw. 
2.) Properly label all tissue culture tubes that will be needed for entire procedure 
(one for each sample + 4 for BSA standards + 1 for blank) Turn on 
spectrophotometer and set wavelength to 595 nm.   
3.) Make serial dilutions of 10 mg/mL BSA such that you end with dilutions of 
1.25, 2.5, 5, and 10 mg/mL.  Aliquot 2.5 mL of diluted protein assay solution 
into 5 tissue culture tubes (one will be your blank the other 4 will be for your 
BSA standards).  Add 5 uL of each BSA standard into its respective tissue 
culture tube; add nothing to the tube designated as the blank.  Vortex each 
tube after protein addition; solution should turn from dark red to blue; 
intensity of blue should increase with increasing protein concentration.  Let sit 
for 5 minutes before reading absorbance.  Signal will deteriorate after 30 
minutes. 
4.) Vortex blank briefly and carefully transfer to an empty, clean cuvette.  Wipe 
the sides of the cuvette carefully with a Kim wipe, place blank into 
spectrophotometer in the correct orientation, and “Blank” the system.  Repeat 
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to take sequential measurements of BSA standards and record the absorbance.  
Dispose of BSA standards and retain blank in curvette, as it will be used for 
the duration of this procedure.  Dispose of used cuvettes and tissue culture 
tubes properly when finished. 
5.) Open an Excel spreadsheet and plot your BSA standard data as absorbance vs. 
[BSA].  Generate a scatter plot and run a linear regression analysis to obtain 
the equation and R^2 value.  If your R^2 is above 0.98, continue to next step; 
if not, repeat starting at step 3.  BSA standard solutions may be stored in 
freezer for up to 1 year. 
6.)  Check homogenized samples on ice.  If fully thawed, prepare tissue culture 
tubes with 2.5 mL protein assay solution.  If not fully thawed, do not agitate 
samples; this will cause proteins to fractionate.  Take thawed sample from ice, 
vortex briefly, and aliquot 5 uL into proper tube containing protein assay 
solution.  Quickly return sample to ice and vortex tube.  Repeat for each 
sample.  Prepare no more than 10-15 samples at a given time to prevent 
possible deterioration of signal.  Return homogenates to -80 ºC freezer as 
soon as possible. 
7.) “Blank” spectrophotometer with blank, and begin taking absorbance 
measurements on homogenate samples.  Record the measurement for each 
sample in your lab notebook.  Dispose of all waste properly. 
8.) With the recorded absorbance data, return to the Excel spreadsheet with the 
BSA standard curve to calculate protein concentration of each homogenate.  
The equation for the standard curve will be in the form y = mx + b, where y is 
the absorbance (Abs; AU) and x is the protein concentration ([P]; mg/mL).  
Rearrange equation to read [P] = (Abs – b)/ m.  Plug in absorbance values to 
determine respective protein concentrations.  Record in lab notebook and 
create a table detailing this data.   
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9.) Manipulate [P] data to determine proper loading amounts of sample for a 
given protein content using either 2X or 4X Laemmli’s buffer. 
 
V. Sample Preparation 
1.) Obtain ice, properly label microcentrifuge tubes, and begin to heat beaker of 
H2O.  Remove protein samples from -80 ºC freezer and place on ice to slow 
thaw. 
2.) Transfer appropriate amount of 4X Laemmli’s sample buffer to each tube.  When 
protein samples are completely thawed, vortex protein sample, and transfer 
sample to tube in a 3:1 ratio (i.e. 25 uL of 4X sample buffer + 75 uL of protein 
sample = 100 uL of prepared sample).  Quickly return original samples to freezer. 
3.) Make sure H2O bath is boiling.  Place samples in sample floater and put in 
boiling water for 5 minutes. 
4.) Remove from H2O after 5 minutes.  Sample can be loaded into a gel when cooled 
to room temperature, or can be frozen for future use. 
 
VI. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Solutions 
1.5 M Tris pH 6.8 
10% APS (make fresh or store at -20 ºC) 
20% SDS 
10X Running buffer   
1X Running buffer 
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1X Running Buffer 
100 mL 10X running buffer 
5 mL 20% SDS 
Bring to 1 L with dH2O 
 
 Procedure 
1.) Gather 15 mL conical tubes, glass slides, and all gel casting equipment.  Label 
tubes to be either the “Stacking Gel” or the “Separating Gel”.  Wipe both sides of 
all glass slide with methanol, and assemble gel casting apparatus. 
2.) Mix both separating and stacking gels simultaneously in their respective tubes 
following the recipes below (DO NOT add APS or TEMED yet): 
 
5% Stacking Gel 8% Separating Gel 10% Separating Gel 
1.25 mL 40% Acrylamide  2.0 mL 40% Acrylamide 2.50 mL 40% Acrylamide 
0.65 mL 2% Bis  0.22 mL 2% Bis 0.27 mL 2% Bis 
1 mL 1.5 M Tris pH 6.8  2.50 mL 1.5 M Tris pH 6.8  2.50 mL 1.5 M Tris pH 6.8 
50.0 Ul 20% SDS 50.0 uL 20% SDS 50.0 uL 20% SDS 
6.99 mL dH2O 5.22 mL dH2O 4.65 mL dH20 
50 uL 10% APS 20.7 uL 10% APS 25.89 uL 10% APS 




10X Running Buffer 
30.28 g Trizma base 
144.2 g  Gycine 
Bring to 1 L with dH2O 
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12.5% Separating Gel 15% Separating Gel 18%  Separating Gel 
3.13 mL 40% Acrylamide 3.76 mL 40% Acrylamide 4.51 mL 40% Acrylamide 
0.35 mL 2% Bis 0.41 mL 2% Bis 0.49 mL 2% Bis 
2.50 mL 1.5 M Tris pH 6.8 2.50 mL 1.5M Tris pH 6.8 2.50 mL 1.5M Tris pH 6.8 
50 uL 20% SDS 50 uL 20% SDS 50 uL 20% SDS 
3.93 mL dH2O 3.23 mL dH2O 2.39 mL dH2O 
32.5 uL 10% APS 38.94 uL 10% APS 46.71 uL 10% APS 
6.25 uL TEMED 7.50 uL TEMED 8.99 uL TEMED  
 
3.) Add APS and TEMED (in that order) to separating gel.  Vortex briefly, and 
pipette into gel casting plates until it is ~2 inches from top of short plate.  
Carefully add butanol over poured separating gel to ensure a smooth surface.  
Allow separating gel to polymerize. 
4.) Once separating gel has polymerized, pour out butanol and rinse thoroughly with 
dH2O.  Absorb excess H2O with KimWipe. 
5.) Add APS and TEMED to stacking gel, and pour over separating gel.  Carefully 
place comb over top and make sure no air bubbles are trapped.  Allow stacking 
gel to polymerize. 
6.) Once polymerized, remove from casting stand and place in electrophoresis 
module with short plates facing inward.  Fill inner space with 1X Running buffer.  
Remove combs. 
7.) Place the sample loading guide over inner space. Load 5 uL of protein marker to 
either outside lane (1 or 10).  Load appropriate amounts of prepared sample into 
correct lanes.  Record this arrangement in lab notebook.   
8.) Remove sample loading guide, fill outer space with 1X Running buffer until 1/3 
to ½ the height of the gel.  Cover with electrophoresis module cover. 
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9.) Turn ON power supply and set to constant current (50 mA for every module 
connected), 200 V, and 200 W.  Run for appropriate time (i.e. when desired 
separation is achieved). 
 
VII. Electro-transfer to PDVF Membrane 
Solutions 
 1 M Tris stock un-pHed 
 20% SDS 
 Anode I solution  
 
Component Reagent and Amount 
300 mM Tris 300 mL of 1 M Tris Stock 
0.05% SDS 2.5 mL of 20% SDS 
10% methanol 100 mL  
10mM β-
mercaptoethanol 0.78 mL 






 Anode II solution 
Component Reagent and Amount 
25mM Tris 25 mL of 1 M Tris Stock 
0.05% SDS 2.5 mL of 20% SDS 
10% methanol 100 mL 
10mM β-mercaptoethanol 0.78 mL 
* Bring to 1 L 
 
 Cathode solution 
Component Reagent and Amount 
25mM Tris 25 mL of 1 M Tris Stock 
40 mM α-amino hexanoic acid 5.248 g 
0.05% SDS 2.5 mL of 20% SDS 
10% methanol 100 mL 
10mM β-mercaptoethanol 0.78 mL 
* Bring to 1 L 
 
Procedure 
1.) Pour an appropriate amount of Anode I solution into a weigh boat. 
2.) Remove gel from electrophoresis module and carefully remove short plate.  
Slowly cut gel at desired molecular weights.  Notch the top corner of lane 1 and 
place in Anode I solution filled weigh boat. 
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3.) Cut a piece of PDVF membrane the size of the gel just prepared.  Mark the upper 
right-hand corner with a pencil.  Place this into pure methanol, then move to 
another weigh boat containing Anode I solution.  Allow to equilibrate for at least 
5 minutes. 
4.) Cut 2 pieces of extra-thick blotting paper that corresponds in size to the 
membrane (2 pieces for every membrane).  Soak 1 of these in Anode II solution. 
5.) Open transfer cell and gently place Anode II solution-soaked blotting paper to 
electrode.  Roll over with test tube to remove all air bubbles.   
6.) Remove membrane from Anode I solution and place on top of blotting paper.  
Roll test tube over. 
7.) Gently place soaked gel over membrane and make sure notched corner lines up 
with marked membrane corner.  Check to see if any air bubbles. 
8.) Soak other piece of blotting paper in Cathode solution.  Remove and place over 
gel.  Roll over with test tube.   
9.) Replace transfer cell cover.  Turn ON power supply and set to 300 mA constant 
current, 25 V, and 200 W.  Time of transfer will depend on size and abundance of 
protein of interest. 
 
VIII. Immunoblotting  
Solutions 
 5 M NaCl 
 1 M Tris pH 7.5 
 0.1% TBST 
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Component Reagent and Amount 
20 mM Tris 20 mL 1 M Tris pH 7.5 
500 mM NaCl 100 mL 5 M NaCl 
0.1% Tween-20 1 mL 
*Bring to 1 L  
Procedure: 
1.) Prepare 25 mL of 5% milk in TBST for every membrane being transferred.  Pour 
milk into plastic shaking dish. 
2.) Remove membrane from transfer cell and place in milk.  Rotate at room 
temperature for at least 1 hour.   
3.) Depending on primary antibody to be used, prepare 5 mL of either 1% milk-
TBST (Santa Cruz antibodies) or 5% BSA-TBST (Cell Signaling antibodies).  
Transfer to a properly labeled 15 mL conical tube.  Add appropriate amount of 
primary antibody to achieve desired dilution (usually 1:1000 works). 
4.) Pour milk out of shaker and add a small amount of TBST to rinse milk off of 
membrane.  Using gloves and forceps, remove membrane from shaker and curve 
to fit into the tube containing the prepared primary antibody solution.  Make sure 
protein covered side is facing inward (i.e. is exposed to the primary antibody).  
Place in 4 ºC rotator overnight. 
5.) Add ~15 mL of TBST to a plastic shaker, and remove membrane from 15 mL 
conical tube to place in shaker.  Rotate at room temperature for 15 minutes.  
Perform 3 washes total.  Return primary antibody solution to 4 ºC.   
6.) Prepare 10 mL of either 1% milk-TBST (Santa Cruz antibodies) or 5% milk-
TBST (Cell Signaling antibodies).  Add appropriate amount of correct secondary 
antibody to achieve a 1:2000 dilution (may need to adjust, depending on antibody 
used).  Rotate at room temperature for at least 1 hour (2 hours for better results). 
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7.) Dump out secondary antibody solution, rinse with TBST, and perform 5 5-minute 
washes with TBST. 
 
IX. Membrane Stripping and Re-probing 
Solutions 
 1 M Tris pH 6.7 
 20% SDS 
 Stripping buffer 
Component Reagent and Amount 
62.5 mM Tris 32.5 mL 1 M Tris pH 6.7 
2% SDS 50 mL 20% SDS 
100 mM ß-mercaptoethanol 3.9 mL 
*Bring to 500 mL  
 1 M Tris pH 7.5 
 5 M NaCl 
 0.1% TBST 
Component Reagent and Amount 
20 mM Tris 20 mL 1 M Tris pH 7.5 
500 mM NaCl 100 mL 5 M NaCl 
0.1% Tween-20 1 mL 




1.) Remove membrane cassette and place back in dH2O filled shaking dish.  Turn 
oven on and let warm to 50 ºC. 
2.) Pour out dH2O, pour in ~10 mL of stripping buffer, and place dish lid 
securely.  Place in oven for 30 minutes, agitating occasionally. 
3.) Prepare 25 mL 5% milk-TBST for every membrane, and pour into a clean 
shaking dish.  Have another clean dish with ~50 mL TBST.   
4.) After 30 minutes, remove dish from oven, remove membrane, and rinse in 
fresh TBST.  Then transfer membrane to 5% milk and begin immunoblotting 
procedure.   
 
X. PEGylated Fibrin gel 
1) Reconstitute fibrinogen at a concentration of 80 mg/mL in PBS (pH 7.8) at 37 
C until it is completely dissolved. 
2) Reconstitute SG-PEG-SG at 4 mg/mL in PBS (pH 7.8).  Vortex briefly. 
3) Add equal volumes of Fibrinogen and PEG solutions, then filter sterilize.  Add 
equal volumes of fibrinogen/PEG mix and 100 ug/mL IGF-I (sterile).  
Incubate mixture at 37 C for 45 minutes. 
4) Induce polymerization of the resulting mix by adding an equal volume of 25 
U/mL thrombin dissolved in 40 mM CaCl2 (pH 7.8). 
 
XI. In situ Force Measurements 
1.) Make an incision on the skin down the midline of the posterior portion of the 
lower limb from the popliteal area t othe calcaneus. 
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2.) Carefully expose the biceps femoris, then cut it to expose the gastrocnemius 
muscles. 
3.) Carefully isolate the gactrocnemius from the biceps femoris.  Cut the 
calcaneus.  Then isolate the gastrocnemius from the soleus and and plantaris. 
4.) Severe the tibial nerve as it enters the medial head of the gastrocnemius. 
5.) Using the calcaneus as an anchor, attach the Achilles tendon to the lever arm 
of the dual-mode servomotor (Cambridge Technologies, model 310 LR). 
6.) Stimulate the muscle to contract using the stimulator (A-M Systems, model 
2100) by placing electrodes on the tibial nerve. 
7.) Keep the muscle warm and moist using 37.5 C mineral oil and a radiant heat 
lamp. 
8.) Determine optimal length by finding maximum twitch force using a 
stimulation of 0.5 Hz. 
9.) Stimulate muscle at 150 Hz to obtain maximum peak tetanic contraction.  
Allow muscle to rest for 2 minutes following each contraction.  Save data to 
computer. 
XII. Tissue Sectioning 
1.)  Set the cryostat specimen head temperature at -20 degrees Celsius.   
2.)  Frozen tissue was transported from the -80°C freezer placed within the 
cryostat chamber.  
3.) Using single-edge razor blades, the portion of the tissue that is important for 
analysis is cut off before mounting onto specimen disks for sectioning. 
4.) Mount tissue onto specimen disks using optimal cutting temperature 
compound (OCT). 
5.) Insert specimen disk into specimen head and orient specimen head if 
necessary. 
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6.) Initially adjust base of the blade holder to bring blade close to tissue using 
coarse feed settings and handwheel. 
7.) Begin sectioning tissue; ensuring sections are sliding under the anti-roll plate. 
8.) Gently place sectioned tissue from blade holder using a microscope slide; two 
tissue sections are placed on each microscope slide. 
9.) Appropriately label microscope slide and place in slide holder for future use. 
 
XIII. H&E Staining  
1) Place the slide in Harris Hematoxylin for 5 minutes. 
2) Perform a gentle tap water rinse until the water runs clear. 
3) Place the slide in Eosin for 2 minutes. 
4) Perform a gentle tap water rinse until the water runs clear. 
5) Rinse slide in 70% ethanol for several seconds. 
6) Rinse in 100% ethanol for several seconds. 
7) Rinse in xylene for several seconds. 
8) Allow slide to dry, then mount a coverslip with Permount. 
XIV. Immunohistochemistry 
1.)  Fix slides with cold acetone (stored in the -4°C chest freezer)  for 7 to 8 mins 
at room temperature 
a. Wash with 1X PBS, 3 times (each 5 mins) 
b. Let it dry until there are no droplets left for ~10 mins 
c. Blot off excess droplets on the sides with Kimwipe 
2.) Put slides in humid box (wet paper towel at the bottom of the box). 
3.) Circle the specimens with the barrier pen and allow ~ 5 mins to dry 
4.) With a dropper add, 5% donkey serum diluted with 1X  PBS & 1% BSA  
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a. Cover the humid box and leave at room temperature for 2 hours 
b. Let sections dry for ~10 mins (slant slides against the wall) 
c. Blot off excess droplets on the sides w/Kimwipe.   
5.) 1º Antibody  
a. For all other primary antibodies, namely Desmin, MyoD, Myogenin 
and Neonatal myosin a 1:200 dilution is used.  All antibodies are 
diluted in 1X PBS & 1% BSA & 5% donkey serum.   
b. Leave overnight in the humid box in 4ºC fridge (~12 hours)    
c. Wash with 1X PBS 3 times (each 5 mins) 
d. Let sections dry until there are no droplets left for ~10 mins 
e. Blot off excess droplets on the sides w/Kimwipe 
6.) 2º Antibody  DO THIS IN THE DARK  
a. 1% of 2º Antibody is diluted in 1% BSA & 5% donkey serum and 
applied to the tissue sections before incubation in the humid boxes.   
b. Put foil over the top of the humid boxes. 
c. Leave slides in the dark in the 4ºC fridge for 1.5 hours 
d. Thaw the DAPI for 45 mins for the counterstain at room temperature.  
DAPI is stored in the -20ºC freezer when not in use.    
e. Wash slides with 1X PBS 3 times (each 5 mins) 
f. Let sections dry for ~10 mins (slant slides against the wall) 
g. Blot off excess droplets on the sides w/Kimwipe 
7.) DAPI (counterstain)  DO THIS IN THE DARK 
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a. Apply 1μL of DAPI + 1mL of 1X PBS to the sections for ~12 to 15 
mins 
b. Wash with 1X PBS 3 times (each 5 mins) 
c. Let it dry for ~30 mins to an hour (slant slides against the wall) 
d. Mount the slides w/Permount and let dry for ~30 mins to an hour. 
 
XV. Collagenase Preparation 
1.) Prepare a 2% collagenase II (Invitrogen) solution in DMEM. 
2.) Filter sterilize the solution (0.2 um filter) and dilute to 1% collagenase with 
DMEM. 
3.) You will need ~1 mL of collagenase solution for every 100 mg of muscle 
tissue.  Aliquot proper amount into sterile 5 mL tube, and freeze the rest in 
properly labeled 15 mL tube. 
4.) Preheat oven with rotator to 37 C.   
XVI. Cell Isolation from Whole Muscle 
1.) Before muscle isolation, prepare a properly labeled 35 mm dish with 3 mL 
sterile PBS for each group.  Keep dishes on ice. 
2.) Isolate muscle, weigh muscle on sterile weigh-boat, and place muscle in 
proper 35 mm dish.  Keep muscles on ice. 
3.) Finely mince muscle with curved scissors on the sterile lid of a 35 mm dish.  
After mincing is complete, add some collagenase solution to lid in order to aid 
in the transfer to the 5 mL tube.  Transfer as much of the minced muscle to the 
tube as possible 
4.) Once all muscles are minced and transferred into proper tubes, securely snap 
lids on tubes, and rotate tubes at 37 C for 20 minutes. 
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5.) After 20 minutes, removes tubes from rotator, and triturate solution with a 
sterile pipette until homogenous mixture is achieved.  Rotate in oven for 20 
minutes. 
6.) Prepare 15 mL tubes with 5 mL of control media.  Filter each 5 mL tube of 
homogenate into the correct 15 mL tube using either a 40 or 100 um filter.  
Make sure to wash filter with control media after all of the solution is 
transferred to prevent loss of cells stuck to filter. 
7.) Spin tubes at 300g for 6 minutes. 
8.) Decant supernatant and resuspend pellet in proper amount of control media 
(typically 1 – 3 mL, based on size of pellet).  Keep cells on ice until plating. 
XVII. Cell Counting with Hemacytometer 
1.) Carefully prepare hemacytometer by placing cover slip in place. 
2.) Prepare counting solutions by mixing 10 uL of cell suspension with 10uL of 
trypan blue.  Transfer 10 uL of mix to hemacytometer. 
3.) Count 4 quadrants on hemacytometer using brightfield microscope on 20X 
objective lens. 
4.) Calculate cell numbers by:  #cells/4 x (2x104) = cells per mL.  Multiply by 
total mLs to get total cell count. 
XVIII. Preparation of Cells for Flow Cytometry 
1.) Prepare three 5 mL tubes for each sample: unstained, isotype control, and 
antibody tubes.  Add 3 mL of FACS wash buffer (1% BSA in PBS + 0.05% 
sodium azide) to each tube. 
2.) Aliquot ~ 1.5x105 cells per tube and spin at 300g for 6 minutes. 
3.) Decant supernatant and add 200 uL FACS blocking buffer (2% BSA in PBS + 
0.05% sodium azide).  Rotate on ice for 1 hour. 
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4.) While blocking, prepare antibody solutions.  Add 1 uL of each antibody or 
isotype controls per 100 uL (100 uL per sample) of FACS blocking buffer into 
the proper tube. 
5.) After blocking is complete, add 3 mL of FACS wash buffer and spin at 300g 
for 6 minutes 
6.) Decant supernatant and add 100 uL of blocking buffer into unstained tubes, 
100 uL of isotype solution into isotype tubes, and 100 uL of antibody solution 
into antibody tubes.  Rotate for 1 hour on ice. 
7.) Add 3 mL FACS wash buffer per tube and spin at 300g for 6 minutes. 
8.) Decant supernatant and resuspend in 200 uL FACS wash buffer. 
















Appendix B:  Raw Data 
 
Maximum Tetanic Force (N) 
Young Old 
Control TK Control TK 
3.15 1 1.5 0.13 
3.85 1.2 2.45 0.55 
3.8 1.26 1.5 0.43 
3.25 0.71 1.75 0.88 
4.1 0.98 1.25 0.23 
2.2 0.78 2.2 0.25 
2.95 1.34 1.02 0.34 
3.3 1.43 2.45 0.64 
3.18   2.61   
3.3   2.75   
3.31   1.96   
3.2   2.32   
4.2   1.98   
2.85   1.7   
2.75   1.85   
4.03   2.03   
3.23   2.31   











Gastrocnemius Mass (mg) 
Young Old 
Control 1 Day 3 Days 5 Days 7 Days Control 1 Day 3 Days 5 Days 7 Days 
160 172 173 128 163 134 173 145 186 103 
139 188 236 158 116 136 188 151 136 92 
184 223 171 180 153 122 149 133 159 120 
179 206 161 138 164 163 191 177 124 81 
154 208 254 157 143 146 188 199 122 115 
157 219 190 174 126 132 207 189 155 64 
171 203   178 133 137 206   89 100 
159 221   173 149 125 182   111 125 
175 219   176 150 106 186   96 114 
176 193   186 138 143 224   116 112 
194 229   165 139 135 204   148 134 
133     173 138 148 174   124 61 
165     185 165 153       94 
190     133 152 131       104 
153     203 153 153       102 
164     176 171 138       92 
162     203 167 145       119 
172     191   154       106 
155         141       111 
169         125         
179         130         
166         134         
158         138         
156         123         
168         110         
171         135         
172         141         
185         133         
166         168         
158         137         
162         134         
162         159         
168         132         
161         96         
148         145         
165         88         
169         119         
159         113         
162         132         
166         126         
156         128         
185         121         
169         152         
169         113         
181         125         
185         117         
178         91         
          105         
          115         
          115         
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F2-Isoprostane Levels (ng/g tissue) 
Young Old 
Control 2 Hour 1 Day 5 Day Control 1 Day 5 Days 
1.67 1.88 1.70 2.61 1.53 1.78 2.93 
1.41 1.74 3.51 2.68 1.44 2.32 3.02 
1.52 2.94 1.75 2.21 1.77 2.44 2.77 
1.09 2.60 1.76 2.84 1.28 1.86 2.80 
1.55 2.06 2.13 1.92 1.19 2.41 2.95 
1.33 2.31 2.29 2.53 1.66 2.92 2.84 
1.33       1.81     
1.74       1.56     
1.51       1.89     
1.09       1.70     
1.17       1.74     
0.93       2.01     
0.89             
1.22             
1.88             
1.34             
0.99             
1.76             
 
 
Relative IGF-I mRNA (AU) 
Young 
Day 1 Day 3 Day 5 Day 7 
Control TK Control TK Control TK Control TK 
1.00 2.74 0.74 19.27 5.31 6.25 0.85 6.77 
1.00 2.93 0.78 23.18 5.27 6.78 0.89 5.98 
1.00 2.33 0.76 22.14 3.7 6.61 0.92 5.66 
Old 
Day 1 Day 3 Day 5 Day 7 
Control TK Control TK Control TK Control TK 
0.53 0.71 0.56 5.33 0.47 8.67 0.46 5.56 
0.52 0.68 0.59 5.39 0.46 7.5 0.53 5.35 
0.42 0.11 0.45 6.43 0.49 8.17 0.55 4.8 
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IGF-I Content (ng/mg tissue) 
Young Old 
Control TK Control TK 
32.19 307.90 40.29 71.71 
56.48 102.67 45.52 33.14 
22.67 124.57 111.71 10.76 
32.67   82.67 17.90 
 
Relative Protein Abundance (AU) 
pAkt (5 Day) Total Akt (5 Day) 
Young Old Young Old 
Control TK Control TK Control TK Control TK 
1.40 0.63 1.29 0.00 1.22 3.16 1.08 1.45 
0.63 0.46 1.17 0.00 1.11 2.42 0.73 1.41 
0.96 0.46 1.23 0.12 0.67 2.02 0.66 1.61 
1.00 0.43 0.44 0.04 1.00 4.54 0.76 1.56 
pAkt (7 Day) Total Akt (7 Day) 
Young Old Young Old 
Control TK Control TK Control TK Control TK 
1.05 0.70 0.73 0.56 1.01 3.93 1.14 4.98 
1.09 0.80 0.67 0.41 1.09 6.08 1.38 4.58 
0.86 0.74 0.96 0.71 0.90 5.12 1.53 4.24 
1.00 0.80 0.45 0.21 1.00 7.68 1.07 5.76 
pmTOR (7 Day) Total mTOR (7 Day) 
Young Old Young Old 
Control TK Control TK Control TK Control TK 
0.92 7.88 1.30 3.51 1.09 5.06 1.71 2.42 
1.08 9.49 1.96 3.35 0.78 5.59 1.03 2.60 
0.56 8.14 1.61 3.46 1.13 4.34 1.59 3.79 
0.84   1.54   0.81   1.23   
1.60   1.01   1.02   1.39   
        1.17   0.86   
pFoxO3 (7 Day) Total FoxO3 (7 Day) 
Young Old Young Old 
Control TK Control TK Control TK Control TK 
1.00 3.00 1.51 1.31 1.00 2.16 0.93 1.87 
1.49 2.38 0.20 1.04 1.15 1.37 0.65 2.64 
0.51 2.06 0.77 0.91 0.85 0.63 0.64 2.26 
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IGF-I Release from PEGylated Fibrin Gel 









1230 41.75 675 64.66 
1059 45.41 514 67.46 
1453 37.81 986 63.47 









691 88.10 275 97.45 
514 89.51 172 96.87 
1147 93.31 182 98.05 









58.16 99.43 14.06 99.90 
58.68 99.39 9.91 99.82 







































Maximum Force Production (N) 
Control Saline bIGF PEG-Fib PEG-Fib-IGF 
26.7 9.8 16.3 15.3 20.3 
31 12.6 9.4 11.4 18.2 
26.8 15.7 11.6 12 22.3 









    
26 13.4 
 
    
24.8   
 
    
23   
 
    
28.3   
 
    
28   
 
    
22   
 
    
24         
 
Muscle Fiber Size Distribution 
Fiber Control Saline Bolus IGF-I PEG-Fib PEG-Fib-IGF 
Size (mm^2) Frequency % Frequency % Frequency % Frequency % Frequency % 
500 0 0.00 40 9.03 16 6.25 2 0.54 0 0.00 
1000 0 0.00 88 19.86 40 15.63 15 4.02 2 0.32 
1500 2 0.48 69 15.58 21 8.20 29 7.77 18 2.84 
2000 7 1.67 43 9.71 41 16.02 40 10.72 39 6.15 
2500 21 5.00 48 10.84 34 13.28 56 15.01 66 10.41 
3000 37 8.81 35 7.90 30 11.72 57 15.28 85 13.41 
3500 59 14.05 29 6.55 20 7.81 34 9.12 110 17.35 
4000 68 16.19 16 3.61 9 3.52 38 10.19 77 12.15 
4500 74 17.62 21 4.74 4 1.56 20 5.36 73 11.51 
5000 72 17.14 9 2.03 5 1.95 28 7.51 45 7.10 
5500 32 7.62 12 2.71 2 0.78 10 2.68 47 7.41 
6000 24 5.71 10 2.26 7 2.73 4 1.07 34 5.36 
6500 14 3.33 5 1.13 8 3.13 13 3.49 21 3.31 
7000 3 0.71 3 0.68 9 3.52 8 2.14 3 0.47 




Muscle Fibers <2000 mm^2 (%) 
Control Saline bIGF PEG-Fib PEG-Fib-IGF 
3.18 47.83 24.59 25.00 13.19 
0.00 52.79 59.29 27.08 5.71 
3.67 69.41 36.36 15.38 6.79 
 
Immunohistochemisty Analysis 



















42.42 13.79 76.92 25.00 57.14 13.51 55.23 13.19 1.16 
38.71 48.00 78.00 29.41 45.31 4.08 58.82 6.72 2.22 
30.43 65.12 94.74 24.24 53.70 0.00 52.94 37.00 7.48 
3.23 56.60 94.12 51.06 28.26 6.00 32.04 1.48 0.19 
29.17 18.52 98.08 20.45 16.98 16.67 17.76 2.06 2.20 
40.54 56.90 95.00 30.77 26.00 16.07 56.58 1.57 2.06 
25.00 47.62 100.00 30.19 18.42 1.61 65.61 29.32 0.00 
45.45 44.74 64.15 60.00 27.78 3.51 31.28 27.06 1.18 
46.00 50.00 97.92 44.90 23.08 7.69 26.59 46.51 1.18 
 
 
Relative Protein Abundance (AU) 
PEG-Fib 
pERK pAkt pmTOR pp70S6K MuRF-1 
1.24 0.94 0.53 0.92 1.86 
0.83 1.10 1.30 1.32 1.20 
0.25 0.85 1.02 1.07 0.64 
1.68 1.10 1.16 0.68 0.30 
PEG-Fib-IGF 
pERK pAkt pmTOR pp70S6K MuRF-1 
1.12 1.89 1.31 1.22 0.09 
0.52 1.15 1.93 3.35 0.21 
0.62 1.39 1.66 1.78 0.07 





Relative Cell Numbers - Day 3 
Lateral Gastrocnemius Tibialis Anterior 
CD 11b Q2 Q4 CD 11b Q2 Q4 
0.97 0.63 0.22 1.80 1.18 0.54 
0.80 0.40 0.19 2.56 1.44 0.80 
0.94 0.52 0.27 0.91 0.51 0.22 
1.20 0.68 0.45 0.99 0.56 0.36 
1.09 0.62 0.31 1.65 0.96 0.51 
Relative Cell Numbers - Day 5 
Lateral Gastrocnemius Tibialis Anterior 
CD 11b Q2 Q4 CD 11b Q2 Q4 
0.50 0.41 0.06 0.75 0.65 0.07 
0.56 0.42 0.11 0.97 0.77 0.14 
1.43 1.21 0.11 0.50 0.41 0.05 




Lateral Gastrocnemius (Relative Cell Numbers) 
Day 3 
Saline PEG-Fib PEG-Fib-IGF 
CD 11b Q2 Q4 CD 11b Q2 Q4 CD 11b Q2 Q4 
0.99 0.65 0.23 1.40 1.08 0.19 1.37 0.88 0.23 
0.81 0.41 0.19 1.16 0.63 0.32 0.97 0.52 0.23 
0.97 0.53 0.27 2.34 1.41 0.78 2.03 1.25 0.60 
1.23 0.70 0.46 1.39 0.83 0.46 1.48 0.91 0.51 
Day 5 
Saline PEG-Fib PEG-Fib-IGF 
CD 11b Q2 Q4 CD 11b Q2 Q4 CD 11b Q2 Q4 
0.52 0.42 0.06 0.51 0.41 0.08 0.34 0.29 0.04 
0.58 0.43 0.11 1.31 0.99 0.23 0.74 0.55 0.13 
1.46 1.24 0.11 1.16 0.95 0.12 0.44 0.37 0.05 




Tibialis Anterior (Relative Cell Numbers) 
Day 3 
Saline PEG-Fib PEG-Fib-IGF 
CD 11b Q2 Q4 CD 11b Q2 Q4 CD 11b Q2 Q4 
1.84 1.20 0.55 2.53 1.80 0.63 1.47 0.88 0.43 
2.62 1.47 0.82 2.64 1.39 1.00 3.62 2.31 0.95 
0.93 0.52 0.23 3.74 2.47 0.97 2.54 1.60 0.72 
1.02 0.57 0.37 0.84 0.57 0.24 0.79 0.46 0.30 
Day 5 
Saline PEG-Fib PEG-Fib-IGF 
CD 11b Q2 Q4 CD 11b Q2 Q4 CD 11b Q2 Q4 
0.77 0.67 0.07 0.16 0.12 0.02 0.22 0.18 0.03 
0.99 0.79 0.15 1.14 0.95 0.13 0.42 0.37 0.04 
0.51 0.42 0.05 0.58 0.50 0.05 0.19 0.15 0.02 
0.71 0.58 0.10 0.31 0.24 0.05       
 
 
Percent Recovery of Gastrocnemius- 14 Days 
Saline Macrophage Treatment 
Force Mass Force : Mass Force Mass Force : Mass 
45.4 66.9 67.8 72.1 88.7 81.4 
69.1 82.4 83.8 90.1 86.5 104.1 
55.9 74.7 74.9 81.9 95.5 85.7 
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